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Multiple Endocrine Neoplasia type 1 (MEN1) is a hereditary cancer syndrome 
characterized by tumors of the endocrine system.  Tumors most commonly develop in the 
parathyroid glands, pituitary gland, and the gastro-entero pancreatic tract.  MEN1 is a highly 
penetrant condition and age of onset is variable.  Most patients are diagnosed in early 
adulthood; however, rare cases of MEN1 present in early childhood.  Expert consensus opinion 
is that predictive genetic testing should be offered at age 5 years, however there are no 
evidence-based studies that clearly establish that predictive genetic testing at this age would be 
beneficial since most symptoms do not present until later in life.  This study was designed to 
explore attitudes about the most appropriate age for predictive genetic testing from individuals 
at risk of having a child with MEN1.  Participants who had an MEN1 mutation were invited to 
complete a survey and were asked to invite their spouses to participate as well.  The survey 
included several validated measures designed to assess participants’ attitudes about predictive 
testing in minors. Fifty-eight affected participants and twenty-two spouses/partners completed 
the survey.  Most participants felt that MEN1 genetic testing was appropriate in healthy 
minors.  Younger age and increased knowledge of MEN1 genetics and inheritance predicted 
genetic testing at a younger age.  Additionally, participants who saw more positive than 
negative general outcomes from genetic testing were more likely to favor genetic testing at 
younger ages.  Overall, participants felt genetic testing should be offered at a younger age than 
   vi 
most adult onset conditions and most felt the appropriate time for testing was when a child 
could understand and participate in the testing process.  Psychological concerns seemed to be 
the primary focus of participants who favored later ages for genetic testing, while medical 
benefits were more commonly cited for younger age.  This exploratory study has implications 
for counseling patients whose children are at risk of developing MEN1 and illustrates issues 
that are important to patients and their spouses when considering testing in children.   
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Multiple Endocrine Neoplasia, type 1 
Multiple Endocrine Neoplasia type 1 (MEN1) is a hereditary cancer syndrome 
characterized by tumors of the endocrine system.  The most commonly associated tumors are 
those of the parathyroid glands, endocrine cells of the gastro-entero-pancreatic tract and the 
anterior pituitary gland.  A clinical diagnosis of MEN1 can be made when a patient presents 
with two of these three classic tumor types or one of these tumors and a family history of 
MEN1 [1]. The majority of MEN1 tumors are not malignant.  However, damaging effects can 
be seen from the continuous overproduction of hormones or the size and location of tumors [2].  
MEN1 is inherited in an autosomal dominant manner meaning that each child of an affected 
person has a 50% risk of inheriting this condition.  It is a rare syndrome with an estimated 
prevalence of 1 in 30,000 [3].  MEN1 appears to have no predilection for any ethnic group and 
has been seen across many different populations.  Improvements in screening and diagnostic 
measures have greatly improved the detection rate of MEN1-related tumors in recent years, 
which has resulted in more successful interventions and decreased mortality.   
Parathyroid Tumors 
Parathyroid tumors are the most common manifestation of MEN1 and have a lifetime 
prevalence of 90-99%  [4] [5] [6] [7].  Both hyperplasia and adenomas can be found in the 
parathyroids of MEN1 patients. Often these are multiple, asymmetric tumors that may involve 
three or four of the parathyroid glands [1].  Parathyroid tumors create excessive secretion of 
parathyroid hormone (PTH) leading to elevated serum calcium levels, which is a condition 
known as primary hyperparathyroidism (PHPT).  PHPT is the first presenting sign in 40-90% 
of MEN1 patients [8] [9] [10] [11].  PHPT is not uncommon in the general population and is 
more common in females than males when sporadic [12].  Overall, MEN1 accounts for 4-5% of 
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PHPT patients [13].  Distinguishing features of PHPT that are suggestive of an MEN1 
diagnosis are a young age of onset, males affected with PHPT, parathyroid hyperplasia rather 
than an adenoma, lower parathyroid hormone levels than sporadic, more severe bone 
involvement, and multigland involvement [1] [12] [14].  Although tumors of the parathyroid 
are rarely malignant, the chronic over-expression of parathyroid hormone can have lasting and 
damaging effects.  Most notable, extended PHPT can lead to renal stones, nephrocalcinosis and 
renal failure.  It can also lead to skeletal problems including osteoporosis usually in the fourth 
decade of life [14] [15] [16]. 
Treatment for parathyroid tumors is somewhat controversial, although surgery is the 
preferred management of PHPT in MEN1 patients.  Indications for a parathyroidectomy in 
MEN1 do not differ significantly from those with sporadic PHPT.  In 1990, the NIH published 
a consensus statement addressing indications for surgery in patients with PHPT which included 
strongly elevated levels of serum calcium and resulting effects of hypercalcemia, lower 
creatinine clearance levels, and significantly decreased bone mass [17].  Timing of surgery has 
also been questioned, mainly because the long-term effects of PHPT are unknown [1] [17].  
This is particularly relevant to patients with MEN1, who are diagnosed with PHPT on average 
30 years younger than sporadic PHPT [1]. 
The overall goal of surgical intervention for parathyroid tumors in MEN1 is to reduce 
disease persistence and recurrence.  The multigland involvement and asymmetrical presentation 
of parathyroid glands can make surgical intervention more complicated in patients with MEN1 
and it is still debated whether a subtotal parathyroidectomy or a total parathyroidectomy with 
autotransplantation is more effective.  A subtotal parathyroidectomy involves the removal of 3 
to 3.5 parathyroid glands.  A total parathyroidectomy with autotransplantation involves the 
removal of all four parathyroid glands and autotransplantation of parathyroid tissue elsewhere 
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in the body, usually to the forearm.  With either surgery, there is a strong concern for 
hypoparathyroidism, which causes low serum calcium levels affecting the nervous system, 
skeletal muscles, and cardiac system [18].  In roughly half of patients, permanent 
hypoparathyroidism can be corrected with autotransplantation emphasizing the importance of 
cryopreservation with either procedure [19].  Both procedures are considered acceptable 
treatment options by the National Comprehensive Cancer Network guidelines [20].  Unlike 
other endocrine tumor conditions, such as Multiple Endocrine Neoplasia type 2, prophylactic 
surgery is not generally recommended.  
Gastro-entero-pancreatic tumors 
 Gastro-entero-pancreatic tumors are the second most common tumor type in patients 
with MEN1 and are found in up to 80% of patients [1] [21] [22].  Unlike most other MEN1 
associated tumors, gastro-enteropancreatic tumors have a high risk of malignancy, with the 
exception of insulinomas.  These neuroendocrine tumors are the most common cause of 
MEN1-related death accounting for two-thirds of young deaths [23].  The most common of 
these tumors are gastrinomas, which make up for roughly 40% of MEN1-related 
neuroendocrine tumors [1].  Gastrinomas lead to elevated gastrin levels and can eventually lead 
to Zollinger-Ellison Syndrome (ZES), a condition that presents with gastrointestinal 
complications including abdominal pain, diarrhea, heartburn, weight loss and gastrointestinal 
bleeding [24] Twenty to twenty-five percent of all patients with Zollinger Ellison Syndrome 
have MEN1 [25].  Patients with MEN1 can have gastrinomas in the pancreas, but most often 
they originate in the duodenum [26].  Both locations carry a risk of malignancy.  MEN1-related 
gastrinomas are usually small and multifocal making them difficult to detect radiographically 
[26].  About 50% of patients with a gastrinoma have already had metastasis at diagnosis [1].  
Surgical intervention for gastrinomas in MEN1 patients is highly controversial.  Some advocate 
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a nonsurgical management option usually involving the use of a proton pump inhibitor to 
reduce gastric acid production.  Others support a more aggressive, surgical approach when the 
tumor reaches 3 cm to prevent further metastasis [1] [27] [28]. 
The second most common neuroendocrine tumor, accounting for 10-12%, is an 
insulinoma [1] [5].  MEN1- related insulinomas are usually benign [29].  Medical management 
for insulinomas is less effective than surgery and therefore, surgery is the preferred treatment.  
A total pancreatectomy carries a high rate of morbidity and mortality and is therefore not 
recommended [2] [30].  However, a distal pancreatectomy with enucleation has been shown to 
have a very high cure rate with a low risk of recurrent disease [31].  Tumors found in the head 
of the pancreas should also be treated with partial pancreatectomy [14,31].  More aggressive 
surgical resection is recommended for MEN1-related insulinomas due to the possibility of 
multiple, small insulinomas throughout the pancreas [25].  
Other hormone-producing neuroendocrine tumors include glucagonoma, vasoactive 
intestinal peptide (VIP) and somatostatinoma.  These tumors are rare but can occur in up to 5% 
of patients with MEN1 [1] [5] [28].  Additionally, up to 36% of patients with pancreatic 
endocrine tumors have a non-hormone secreting tumor that may have no clinical implications 
except for the size, mass-effect, and malignant potential [32].  
Pituitary tumors 
Tumors of the anterior pituitary affect 20 to 65% of MEN1 patients [8] [11] [15] [33].  
Pituitary tumors are the first presenting manifestation in roughly 17% of MEN1 patients [8] 
[33].  These tumors can be either non-functioning in 11 to 38% [5] [33] [6] or hormone 
secreting.  The most common type of MEN1-related pituitary tumor is a prolactinoma.  Other 
hormone secreting pituitary tumors include growth-hormone-secreting (5-10%), which can 
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cause acromegaly, and ACTH-secreting (2-5%), which can cause Cushing’s disease [1] [28] 
[30].  Most tumors are macroadenomas and can have severe mass effects, although most are not 
malignant [33].  Pituitary tumors are rarely the only MEN1-related tumor seen in a patient and, 
therefore, often serve as the second tumor in a clinical diagnosis [33].  An isolated pituitary 
tumor is not highly suggestive of MEN1 as pituitary lesions have been seen with MRI in 16% 
of the general population [34].  MEN1 is thought to be responsible for only 2.7% of isolated 
pituitary adenomas [21]. 
Treatment for pituitary tumors in patients with MEN1 is identical to treatment for 
patients with sporadic pituitary tumors.  This treatment includes surgery, medical management, 
and/or radiation [14][28].  However, success rates do not seem to be as high in patients with 
MEN1 as it is in patients with sporadic tumors [33] and continued screening is recommended to 
avoid a recurrence [1]. 
Other MEN1-associated tumors 
Other tumors have been associated with MEN1 less commonly than the three main 
tumor types.  Five to ten percent of patients are diagnosed with a foregut carcinoid.  Of these, 
bronchial and gastric carcinoids are less likely to be malignant while thymic carcinoids can be 
aggressive and are a major cause of mortality among MEN1 patients [4][35].  Often, a subtotal 
or total parathyroidectomy to treat a parathyroid tumor will include removal of the thymus to 
avoid potential future thymic carcinoids.  Adrenocortical tumors and benign thyroid tumors 
may also be caused by mutations in the MEN1 gene.  Some association has been seen with 
renal angiomyolipoma, and leiomyomas of the esophagus [5].  Collagenomas are seen in up to 
72% of patients and lipomas are seen in roughly 34% [36] [37]. Several rare skin findings have 
also been associated with MEN1.  Multiple facial angiofibromas are seen in 20 to 88% of 
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patients with MEN1 [36] [37].  Given the rarity of angiofibromas in the general population, 
MEN1 should be a highly considered differential diagnosis in their presence.  
 Age of Diagnosis 
 MEN1 is a highly penetrant condition with 90-100% of patients exhibiting clinical 
manifestations by age 60 years [4] [8] [38]. A few reports of patients diagnosed before age 10 
years have been published, although this is rare.  These include a five-year old diagnosed with a 
pituitary macroadenoma [39], and two eight-year olds diagnosed with an insulinoma [40] [41]. 
Despite rare reports of children younger than ten being diagnosed with symptoms of MEN1, 
the overall penetrance is reported to be only 7% for this age group [38].  Penetrance increases 
to 52% by age 20 and reaches 98% by age 40 [38].  Studies investigating penetrance and age of 
onset have all been retrospective but have generally found the average age of diagnosis to be in 
early adulthood [4] [8].  Specifically, primary hyperparathyroidism was diagnosed on average 
by age 37 years, pituitary tumors by age 40 years, and GI endocrine tumors by age 46 years [8].  
However, the wide range of ages observed for the diagnosis of each tumor type emphasizes the 
extreme variability in age of diagnosis.   The average age of death related to MEN1 appears to 
be around age 50 years most commonly due to neuroendocrine tumors [8] [23].  It has been 
noted that there is a higher rate of diagnoses at young ages within the past decade, which is 
likely attributable to improved screening [35]. Males and females are affected in equal 
numbers, although recent data suggests a slight difference in phenotype, with men having a 
higher prevalence of pancreatic and thymic tumors while women have a higher prevalence of 
pituitary tumors.  There appears to be no differences between genders in the rate of 
hyperparathyroidism or positive genetic tests [42]. 
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Screening  
Over the past few decades, screening methods have drastically improved resulting in 
earlier intervention and decreased morbidity.   In 2001, an international group of clinical 
endocrinologists published a set of guidelines for diagnosis, treatment and screening of MEN1 
[1].  Since its publication, this has been widely accepted as the consensus protocol, although 
additional groups have published other guidelines that only slightly differ in age and frequency 
of screening [30].  Because most endocrine tumors are functional, biochemical screening has 
proven to be an effective modality.  Additionally, imaging techniques are often able to detect 
smaller lesions and non-functioning pituitary and pancreatic neuroendocrine tumors.  In 
general, biochemical testing is recommended on an annual basis while imaging studies are 
generally recommended every 1 to 3 years or when biochemical tests are abnormal.     
For parathyroid tumors, screening of calcium and parathyroid hormone levels has been 
recommended as early as age 8 years, although others have suggested postponing screening 
initiation until age 20 years, which is closer to the average age of onset for primary 
hyperparathyroidism [1] [30].  These levels can also be used to test post-operative success and 
monitor for signs of recurrent disease following surgery.   
Screening for functional pancreoenteric tumors can be done by evaluating their 
respective biochemical markers following a fasting period. Because insulinomas have been 
identified in patients at a particularly young age, screening is recommended beginning at age 5, 
whereas screening for gastrinomas can be delayed until age 20 years [1].  Regular imaging, 
including computed tomography (CT) scan and magnetic resonance imaging (MRI), are 
recommended to detect non-functional pancreoenteric tumors which may not be found through 
routine biochemical screening [1] [7].  
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Screening for pituitary disease is recommended beginning at age 5 [1] due to a reported 
pituitary macroadenoma in a 5-year-old patient [39].  Laboratory tests include monitoring 
prolactin and insulin-like growth factor 1 (IGF-1) [1] [30]. MRI of the pituitary is 
recommended every 3 years, regardless of biochemical results.  Screening should continue after 
surgical treatment due to the lower curative success rates in MEN1 patients compared with 
those who have sporadic pituitary disease [33]. 
Many of the less commonly associated tumors do not hypersecrete hormones: therefore, 
screening guidelines tend to focus on imaging techniques rather than biochemical analysis.  The 
main recommendation for the detection of carcinoid tumors is a CT scan or MRI every 3 years 
beginning at age 20 [1].   
Consensus guidelines tend to recommend screening at a younger age than the average 
age of onset because of a few reported MEN1 diagnoses before 10 years of age.  However, 
several authors have suggested that these recommendations are unnecessarily aggressive. A few 
have stated that biochemical screening can be postponed until 15 years for pituitary tumors and 
20 years for all other types of tumors, with imaging being performed every three years or only 
if biochemical tests are abnormal [30].  Guidelines have been difficult to establish given the 
debate surrounding implications of an abnormal test result.  The penetrance of biochemical 
signs in asymptomatic patients is up to 43% by age 20 years, more than twice the penetrance of 
MEN1 disease in symptomatic patients [11].  Similarly, it has been suggested that the low 
penetrance among younger age groups may be an underestimate and that asymptomatic 
children may actually have non-functioning neuroendocrine tumors [43].  The nature of these 
tumors in particular can be difficult to predict and surgery at a young age can have its own 
complications.  
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Studies have shown that genetic testing has allowed for earlier screening and can detect 
biochemical changes 10 years prior to the development of disease symptoms [2].  However, 
timing for surgical intervention is debated and often delayed until a child begins to show 
symptoms regardless of prior biochemical or radiographic findings [1].  The NIH consensus 
statement on primary hyperparathyroidism in adults recommends medical monitoring for 
asymptomatic patients with biochemical evidence of primary hyperparathyroidism and has 
specific criteria before beginning surgical intervention [17].  Guidelines are less clear for an 
appropriate time for intervention in children.  This has raised the question of the benefits of 
presymptomatic screening, which poses potential risks for increased stress and anxiety in 
children and their parents, before any treatment would be indicated.  
Molecular Genetics of MEN1 
 In 1997, mutations in the MEN1 gene on chromosome 11q13 were found to be 
associated with the clinical diagnostic criteria for multiple endocrine neoplasia type 1.  MEN1 
is comprised of 10 exons, which code for the 610 amino acid protein, menin [44].  This protein 
has been shown to play a role in DNA replication and repair, transcriptional regulation, cell 
division and proliferation [3].   MEN1 is suspected to have a tumor suppressor role that follows 
Knudson’s “two-hit” model as the majority of tumor cells show loss of heterozygosity [45].  
This theory matches an autosomal dominant inheritance whereby a germline mutation in one 
allele accounts for the first “hit”, and the second is due to a somatic mutation that then leads to 
tumor initiation and growth [46]. 
 Over 450 germline mutations have been identified in the MEN1 gene.  Most mutations 
are frameshift insertions or deletions (41%) followed by nonsense mutations (23%), missense 
mutations (20%), splice site mutations (9%), in-frame deletions and insertions (6%) and large 
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deletions (1%) [47]. Mutations have been found throughout the coding regions and non-coding 
regions and no genotype-phenotype correlations have been identified.   Sequencing is 
commercially available and is the most effective method of genetic testing.  The detection rate 
for an MEN1 mutation in people who meet a clinical diagnosis of MEN1 is about 65% for 
patients with a non-familial presentation [48] and up to 90% in patients meeting a familial 
MEN1 clinical diagnosis [28].  Additionally, 4% of mutations are large deletions that can be 
detected using multiplex ligand-dependent probe amplification (MLPA) [49].  In the event of a 
negative results, an MEN1 diagnosis cannot be ruled out, particularly for patients who meet 
clinical diagnostic criteria [28]. Medical management for these patients is the same as those 
with an identified mutation.  Approximately 10% of patients have a de novo mutation [38].  
Genetic Testing in Minors 
Over the past several decades, genetic testing has become more widely available for 
numerous genetic conditions and access to testing is improving.  Genetic testing is frequently 
used for symptomatic patients as a diagnostic tool to confirm a suspected genetic condition.  
Establishing a genetic diagnosis can direct personalized medical care because it provides 
patients and physicians with information regarding natural history and prognosis.  In oncology, 
genetic testing has been used for many cancer syndromes to provide information regarding 
risks for second primary cancers or responses to various treatments.  For symptomatic 
individuals, this diagnostic advancement has clearly demonstrated benefits in helping to 
diagnose and understand disease. 
Genetic testing can also serve as a powerful predictive tool for the asymptomatic 
individual.  Many hereditary cancer syndromes have prophylactic treatment options or 
increased surveillance methods.  For many conditions, predictive genetic testing can also help 
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individuals anticipate and psychologically plan for a medical condition they may someday face.  
However, there are potential psychological risks associated with predictive testing in an 
asymptomatic individual; therefore, the appropriate age for predictive genetic testing for adult 
onset conditions is typically considered as the age of consent, and testing in minors is highly 
debated. 
Professional Guidelines 
Conditions for which genetic testing is available can be divided into three main groups 
with regards to the impact on minors: conditions for which there is an immediate medical 
benefit, conditions for which any medical benefit would be delayed until adulthood, and 
conditions where there is no known medical intervention that would affect disease severity.  
Several professional organizations have issued position statements regarding genetic testing in 
minors.  In 1995, the American College of Medical Genetics (ACMG) and the American 
Society of Human Genetics (ASHG) issued a joint position statement acknowledging the 
importance of balancing medical and psychological benefits, family structure, and the decision-
making capabilities of the minor [50].  The statement asserts that genetic testing in minors is 
justified when an immediate medical or considerable psychological benefit exists.  When 
medical and psychosocial benefits would be deferred until adulthood, genetic testing should 
also be deferred until the patient is no longer considered a minor.  For conditions in which the 
benefits and harms are unclear, decisions about genetic testing should be left up to the family 
and competent adolescents.  
The American Medical Association (AMA) issued a similar set of recommendations in 
1995 adding that genetic testing should be encouraged, if not required, if therapeutic measures 
are available [51].  The recommendations also noted the importance of making parents aware 
of genetic testing for adult onset conditions so they may inform their children of its availability.  
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The recommendations considered the possibility of testing for the benefit of other family 
members, and indicate that such testing should only be undertaken if not doing so would 
provide considerable harm to the at-risk family member. 
Clinical manifestations of MEN1 are complex and thus interpretation of general testing 
guidelines for minors is not as straightforward compared with other syndromes.  Most persons 
with MEN1 are not diagnosed with a syndrome-related tumor until young adulthood.  Although 
some persons will begin to show signs of hyperparathyroidism in adolescence, surgical 
intervention may not necessarily take place during childhood.  For most patients with MEN1, it 
is unclear if there is a direct medical benefit to testing before adulthood.  However, rare reports 
exist of clinically diagnosed MEN1 in patients under the age of ten, suggesting that there may 
be a rare medical benefit [39] [41].  For this reason, most guidelines suggest beginning 
screening at age 5.  However, these guidelines rarely take into account any potential 
psychological sequelae for both children and parents associated with frequent screening at a 
young age for a condition that often does not present until later in life. 
Given the potential for a significant psychological impact of predictive testing on 
healthy minors, several authors have looked at the potential effects on minors and their 
families.  Childhood and adolescence are marked by changing opinions and developing thought 
processes.  As they are growing, children begin to form an individualized image that can be 
greatly shaped by outside events in their lives. It has been suggested that results of predictive 
genetic testing in minors, particularly positive results, may interfere with development of a self-
concept and cause children to identify themselves by the disease they have inherited but are not 
yet exhibiting [52].  Particularly at young ages, many children may perceive disease and illness 
as a sort of punishment [53] which may influence their developing self-image.  On the other 
hand, it has been suggested that providing genetic risk information to children at a young age 
could facilitate children’s adjustment to their carrier status earlier as opposed to the jarring 
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experience of learning it later in life and perhaps not being given the opportunity to incorporate 
this information into their life plans [54]. 
As children continue to develop their self-image and self-concept, predictive genetic 
testing may potentially impact not only the child but also family and sibling relationships.  
Stigmatization is an important consideration for persons who receive mutation positive 
predictive genetic testing results.  Examples include lowered expectations of mutation positive 
persons within a family or feelings of unworthiness [53]. Children who have inherited a genetic 
mutation associated with a hereditary condition may be impacted as parents struggle with ways 
to express their own guilt about having passed on this genetic condition.  Additionally, several 
authors have pointed to the idea of “vulnerable child syndrome,” where parents are 
overprotective of children who they perceive to be at risk of an early death because of an illness 
or previous close call [53] [55] [56].  Sibling relationships also may be strained when a child 
tests positive for a genetic condition, particularly if the other child tested negative.  This can 
occasionally lead to feelings of survivor’s guilt in the unaffected child [53]. 
A commonly cited reason for genetic testing in minors is to reduce the anxiety of the 
parents who perceive that the burden of uncertainty is greater than the knowledge of what lies 
ahead.  However, justifying predictive genetic testing for adult onset conditions in 
asymptomatic children for the benefit of the parents may be viewed as a direct challenge to the 
child’s autonomy [52].   In most legal systems, parents have the right to make medical 
decisions for their children until they reach the age of legal adulthood (usually 18 years) or 
until the child has become an emancipated minor.  However, it has been advocated that most 
children may be able to understand, to some degree, the implications of their medical care and 
as such, should have an adequate say in the type of medical treatment they receive [53] [57].  
Therefore, there is often a requirement to have a child assent to a procedure or test before they 
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have acquired the ability to fully consent [53].  This often begins when children reach age 7 
while acknowledging that children have varying rates of development and maturity [50] [53].  
It is assumed that a child competent of assenting is capable of understanding a medical 
procedure and is able to agree or disagree with a parent’s decision.  The principles of informed 
consent takes this understanding a step further whereby an individual is not only able to explain 
the procedure and testing that will take place, but also exhibits a voluntary desire to have the 
testing, a clear understanding of the risks, benefits, and alternative options, and recognition of 
the direct and indirect impacts a test can have on the individual, family members or others [52] 
[53].  It is difficult to state at what age a person is capable of providing adequate informed 
consent given the differing rates of maturity.  However, in most legal systems the age of 18 has 
been established as a point at which most individuals can make comprehensive decisions about 
their own health, medical care, and personal rights. 
Upholding a child’s future autonomy is important in maintaining their ability to make 
independent decisions for their own life plan and health care management.  Genetic testing 
affords the ability to predict an outcome that previously would have been left unknown until 
the development of disease.  But with advances in genetics, patients have had to balance their 
rights to know their medical future with their rights not to know what lies ahead [57].  In fact, 
since the discovery of the HD gene responsible for Huntington disease, the uptake of genetic 
testing has only been between 5-20% [58]; albeit there are no medical interventions available to 
reduce the burden of Huntington disease.  Among the most commonly cited reasons for 
declining genetic testing for Huntington disease has been a lack of cure and, therefore, the 
emotional pain of knowing the inevitable outcome is greater than the burden of not knowing 
[59].  Parental decisions to initiate genetic testing in asymptomatic minors deny them their 
ability to weigh these pros and cons and take away their right to decline testing. 
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Parental Opinions 
Balancing the perceived risks of predictive genetic testing in minors with the desires of 
parents to do what they believe is in the best interest of their child and their family can be 
difficult, especially when parents are the ones affected.  Several studies have investigated 
parental opinions regarding predictive genetic testing for various conditions.  Familial 
adenomatous polyposis (FAP) is a hereditary cancer syndrome characterized by hundreds of 
colon polyps and a very high risk for colon cancer if left untreated.  Parents of children at risk 
of inheriting FAP have cited seeking out increased surveillance measures and prophylactic 
options as reasons for supporting genetic testing in children [60].  Screening recommendations 
for FAP include initiating annual colonoscopies beginning at age ten, since the average age of 
onset of colon polyps is around 16 years [61].  Therefore, a second commonly cited reason for 
genetic testing is to prevent unnecessary screening in children who test negative.  Other reasons 
parents have cited for genetic testing include reducing anxiety and increasing knowledge [59] 
[60] [62]. 
In contrast to FAP, parents of children at risk of developing hereditary breast and 
ovarian cancer generally support postponing genetic testing until adulthood.  Hereditary breast 
and ovarian cancer is characterized by up to an 87% lifetime risk of breast cancer and up to a 
44% risk of ovarian cancer [63].  Screening is usually recommended beginning at age 25 or at 5 
to 10 years earlier than the youngest age of diagnosis in the family.  A study of BRCA mutation 
carriers by Bradbury et al. [64] found that 55% were completely opposed to genetic testing in 
minors with the most commonly cited reasons being that there is no medical indication for 
testing (46%), that it would cause fear and anxiety (46%), and that minors are not mature 
enough for the information (46%).  Twenty-four percent indicated that genetic testing should 
only be considered in minors under specific circumstances with the most common situations 
being that the child is exceptionally mature (39%) and there is a potential medical risk that 
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could be mitigated by knowing the result of the genetic test (33%).  The overall consensus 
among parents who are BRCA1/2-mutation carriers is that due to the later age of onset for 
HBOC, genetic testing in most circumstances should be deferred until adulthood when children 
are mature enough to make their own decisions.   
Borry et al. [65] reviewed 14 sets of guidelines from 24 professional organizations 
about carrier testing (i.e. testing for information on reproductive risk rather than personal 
medical risk) in minors and found that the majority of guidelines endorsed not performing 
carrier testing in children but rather deferring testing until a time when children can give 
adequate informed consent.  Although many guidelines established a critical difference 
between childhood and adolescence in regard to the ability to provide adequate informed 
consent, few established an exact age at which a child should make their own decisions about 
testing and stated that it depended on the maturity of the child.  However, many guidelines and 
authors have pointed out that carrier status can have an effect on future offspring and therefore 
consider reproductive age, as opposed to legal adulthood, as an appropriate age for young 
persons to give informed consent regarding carrier testing.   
With regard to hemophilia A and B, which are X-linked conditions, parents may be 
more inclined to favor genetic testing at a younger age with one study reporting a majority 
(84%) of parents wanting their daughters to be tested before age 14 [66].  In this study, the 
primary reason parents who supported genetic testing at a younger age gave was to enable their 
daughters to prepare for their own future children.  Given the de novo rate of hemophilia, many 
mothers are not aware they are carriers until they have a son who is diagnosed with hemophilia.  
It is important to note, however, that girls who are carriers of X-linked conditions can exhibit 
some symptoms due to skewed X-inactivation.  Therefore, genetic testing for minors at risk of 
being a carrier for hemophilia is not always presymptomatic.  This is similar to patients with 
MEN1 who may not show any medically harmful symptoms of disease until they are older than 
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18 years, but it is not uncommon for patients to begin to show signs such as PHPT at an earlier 
age. 
To our knowledge, no studies have investigated parental preferences regarding MEN1 
genetic testing in minors.  Two studies examining the quality of life for patients with MEN1 
highlighted the challenges of the condition including physical and psychological pain, guilt and 
an overall pessimistic outlook [67] [68].  However, it has also been reported that patients with 
MEN1 develop adequate coping mechanisms and tend to adjust well to their situation.  
Currently, decisions about MEN1 genetic testing in minors is based on individual physician’s 
discretion.  Assessing the opinions of patients with MEN1 will provide important insight from 
those who have first-hand experience of the condition.   
The aim of this study is to evaluate attitudes about MEN1 genetic testing for healthy 
minors among adults with an MEN1 diagnosis and/or their partners.  We hypothesize that 
affected participants will be more likely to favor genetic testing in minors than their partners or 
spouses and that those with a younger age of diagnosis will be more likely to favor genetic 
testing in minors than patients with an older age of diagnosis.  Findings from this study may 
help physicians and genetic counselors to better counsel their patients about an appropriate age 
for testing. 
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Materials and methods 
This cross-sectional study was designed to evaluate attitudes towards predictive MEN1 
genetic testing in healthy minors among individuals at risk of having a child with MEN1.  This 
study was approved by the MD Anderson Cancer Center’s (MDACC) Institutional Review 
Board (2006-0783) and the Committee for the Protection of the Human Subjects at the 
University of Texas Health Science Center (HSC-MS-11-0433). 
Study Population 
Study participants were recruited from two sources.  One hundred nine eligible patients 
with MEN1 were identified from a database maintained by the Department of Surgical 
Endocrinology at MDACC.  Eligible patients were able to read and write in English, were age 
18 years or older, and had an identified mutation in the MEN1 gene.  Additionally, MEN1 
patients were asked to invite their spouses or long-term partners to participate in the study.  
Eligible spouses and long-term partners also were above the age of 18 and were able read or 
write in English.   
Participants also were recruited from an online advertisement through the online 
Association for Multiple Endocrine Neoplasia Disorders (A.M.E.N.D.) support group.  These 
participants were directed to an online version of the questionnaire.  Eligibility was confirmed 
through a series of screening questions prior to beginning the questionnaire.  Persons with an 
MEN1 genetic mutation and their spouses or partners were invited to participate.  Individuals 
who stated they did not have a confirmed MEN1 mutation were excluded from the study.  
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Data Collection 
 Eligible patients from the MDACC database received a study packet by mail.  Each 
packet contained a cover letter (Appendix A), a questionnaire for the affected participant 
printed on white paper (Appendix B), a questionnaire for the affected participant’s spouse or 
long-term partner printed on yellow paper (Appendix C), and two postage-paid business reply 
envelopes.  The cover letter included a description of the study, a link to the online version of 
the questionnaire, and directions for both the MEN1-affected participant and partner to 
complete and return the questionnaire.  Packets were mailed only to affected individuals, who 
were given the option of distributing it to the partner or co-parent they felt most appropriate to 
complete the questionnaire.    Each questionnaire was de-identified, but was coded with an 
identification number for tracking purposes and to match questionnaires from affected 
participants with their spouse/partner.  MDACC patients who completed the online version of 
the questionnaire were asked to provide their tracking number.  Both the online questionnaire 
and the paper questionnaire contained the standard questionnaire consent paragraph approved 
by the MDACC IRB.   
Study packets were mailed in mid-December, 2011.  A second packet with a reminder 
letter (Appendix D), two business reply envelopes, and a second copy of each questionnaire 
was mailed to participants six weeks after the initial mailing.  In addition, an advertisement 
containing a link to an online version of the questionnaire was posted on the A.M.E.N.D. 
website under its research section in mid-December, 2011.  Data collection was completed on 
February 23, 2012. 
The online version of the questionnaire was developed using SurveyMonkey®, a 
confidential, online survey-making tool.  Those who completed the online questionnaire were 
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required to provide informed consent and confirm eligibility through a series of preliminary 
questions.  Once eligibility was confirmed, participants were directed to the online 
questionnaire, which was identical to the paper version.  
Measures 
 The study questionnaire was comprised of six sections, which included several 
validated measures as well as tools adapted from previous studies.  The six sections included 1) 
demographic characteristics of the MEN1-affected participant or partner and the MEN1-related 
medical history (MEN1 patients only); 2) demographic and MEN1-related medical history of 
the participant’s children; 3) knowledge of MEN1-associated risks and inheritance; 4) the 
Impact of Event Scale to assess distress response related to an MEN1 diagnosis; 5) the 
Pediatric Testing Attitudes Scale (P-TAS) to measure attitudes towards predictive testing in 
minors; 6) a decisional balance measure weighing the pros and cons of genetic testing in 
minors.  The questionnaire also included an open-ended, free hand response question asking 
participants to identify their perceived ideal age for genetic testing and reasons for selecting the 
age.  
Demographic information 
 For each participant, we assessed age, gender, country of residence, marital status, 
highest level of education completed, occupational status, and household income.  Partners 
were asked to identify their relationship to the affected individual and any at-risk children.  
Affected participants self-reported the type of tumor with which they had been diagnosed 
(parathyroid, pituitary or pancreatic/stomach/intestinal) and at what age.  They were also asked 
if any tumor had metastasized and what age they were when they were first diagnosed with 
MEN1. 
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Family History Information 
All participants were asked to identify the number of people in their family that were 
affected with MEN1, how many people in their family had died from complications related to 
MEN1, how many people in their family had been diagnosed with an MEN1-related tumor 
before age 18, and their perceived severity of MEN1 in the family.  Perceived severity was 
measured on a Likert scale ranging from 1 (not at all) to 5 (greatly). 
 Demographic and medical history also was collected for at-risk children.  For 
participants recruited from MDACC, only affected participants were asked to complete the 
section about their children and their responses were linked to their corresponding partner’s ID 
number.  Data collected included age, gender, diagnosis of a MEN1-related tumor and at what 
age, age and results of child’s genetic testing, and communication of the family’s MEN1 status 
with the child.  Participants were asked to complete these questions for each of their children.   
Knowledge  
 To assess the participants’ understanding of the natural history and inheritance of 
MEN1, participants were asked to answer true, false or unsure to eight statements about MEN1.  
Scores were summarized as the number correct out of the total.  After data collection was 
completed, it was determined that the following item was ambiguous, and therefore was not 
included in the data analysis: “A person who carries an altered MEN1 susceptibility gene will 
definitely develop features of MEN1 in his or her lifetime.”   
Impact of Event Scale 
 The Impact of Event Scale was designed by Horowitz, et al. [69] as a measure of 
distress responses anchored to a specific event.  This scale includes 15 items that assess both 
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avoidance and intrusion responses to a specific event. Intrusion was characterized by the 
presence of unintentional thoughts, dreams, and images, as well as waves of emotion.  
Avoidance includes denial of the impact of an event, feelings of numbness, and behavioral 
inhibition.  It has been commonly used to assess levels of post-traumatic stress in various 
groups of patients.  The Impact of Event scale was used in this study based on clinical 
observations of high levels of anxiety in patients with MEN1 and studies that have found 
patients with MEN1 to have an overall pessimistic outlook [67] [68].  Participants in this study 
were asked to think about their experience with MEN1 in the family and indicate how often 
each item had happened to them in the past seven days.  Responses were measured on a 4-point 
scale ranging from not at all to often.  Higher scores indicated higher levels of distress related 
to an MEN1 diagnosis.   
Decisional Balance 
The decisional balance scale is a component of the transtheoretical model (TTM), which is a conceptual framework often used in health promotion and behavioral change studies to assess a participant’s willingness to adopt a new health behavior.   One component of the TTM is the stage of change construct which identifies a participant’s degree, or stage of readiness to adopt a target behavior and generally includes the following: precontemplation, contemplation, preparation, action, maintenance and termination[70] [71]. Decisional balance is a second component of the TTM framework and is aimed at understanding the importance of pros and cons of a given behavioral change to the participant [72]. The decisional balance may vary depending on an individual’s stage of readiness to change:  at contemplation, the pros of undertaking a specific behavior change may be weighed equally with the cons of doing so; whereas, in 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later stages, when a participant is more likely to change their behavior, the pros are more likely to outweigh the cons [73].   
The decisional balance measure used in this study included items describing pros and 
cons that addressed considerations related to genetic testing in healthy minors and was adapted 
from measures used in previous studies about genetic testing [74] [75].   Fourteen items were 
included (seven perceived pros and seven perceived cons).  Participants were asked to rate the 
level of importance for each factor on a 5-point Likert scale (1=not important, 5=very 
important) when considering having their child tested for MEN1.  Higher scores on the 
decisional balance suggest that the pros outweigh the cons in decision making, whereas lower 
scores indicate a stronger view of the negative consequences of genetic testing. 
Pediatric Testing Attitudes Scale (P-TAS) 
 The Pediatric Testing Attitudes Scale (P-TAS) was used to measure participants’ 
attitudes about predictive MEN1 testing in minors.  The scale was originally created by Peshkin 
et al. [76] to measure parents’ opinions about genetic testing in minors for hereditary breast and 
ovarian cancer (BRCA1/2).  For our purposes, the questions were adapted to apply to MEN1.  
The P-TAS scale is an 11-item measure that comprises two factors: Attitudes and Beliefs (odd 
numbered items) and Decision Making and Communication (even numbered items). Items 
measuring attitudes and beliefs are intended to capture parents’ theoretical opinions about 
genetic testing while the decision making and communication items describe the importance of 
involving the child and others in the decision to have genetic testing and disclosure of the 
results.  Participants were asked to rate their responses from 1 to 5 (1 = strongly disagree and 5 
= strongly agree) for each item.  Higher scores on the P-TAS measure indicated stronger 
preferences towards predictive testing in minors.   
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Ideal Age for Testing 
A single item, open-ended question asked respondents what their opinion regarding the 
ideal age for predictive MEN1 genetic testing was and why they chose this age (Appendix E).  
This item was also used to capture any additional comments about an appropriate age for 
genetic testing.   
Data Analysis  
Summary statistics (i.e. mean, percent, range, SD) were computed for all demographic, 
medical, and family history variables.  Knowledge scores were calculated as the percent 
correctly answered. Each response from the IES scale was summarized with point values 0, 1, 
3, and 5 and scores were calculated separately for the Intrusion and Avoidance subscales and 
for the overall measure.  Possible scores could range from 0 to 35 for the Intrusion subscale, 
from 0 to 40 for the Avoidance subscale, and 0 to 75 for overall IES score.  The decisional 
balance measure in this study was adapted from a previously developed measure [75].  The 
decisional balance score was first calculated by subtracting the sum of cons items from the sum 
of pros items.  Raw scores were converted into T scores with a mean of 50 and a standard 
deviation of 10 for further analysis.  Overall decisional balance scores were calculated by 
subtracting T scores of the cons from T scores of the pros.  Participants were given the option 
of skipping questions they were uncomfortable with and so response rates varied by question.  
Missing data in the knowledge section was coded as false.  Missing questions in the IES, 
Decisional Balance and P-TAS were replaced with the average score from the other questions 
answered in the same subscale. 
Scores for each factor of the P-TAS measure were calculated independently and jointly 
as a total P-TAS score.  For Factor 1 (Attitudes and Beliefs) and Factor 2 (Decision Making 
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and Communication), the possible range of scores was 6 to 30 and 5 to 25, respectively.  The 
possible range for total PTAS score was 11 to 55. 
For the ideal age, because many participants gave a range of ages (i.e. 8-10) or vague 
description (i.e. before puberty, when the child is old enough to understand, at a young age, 
etc.) this item could not be analyzed as a continuous variable.  For purposes of analysis, ideal 
age was coded as either childhood (≤14 years), high school and above (>14 years), or 
indeterminate by two independent reviewers.  Responses such as “as soon as possible” and 
“before puberty” were included in the ≤14 category.  Age 14 was chosen as the cutoff given 
that this is the age when most children have already started undergoing puberty, are entering 
high school and have entered the transition period between childhood and adulthood, and are 
taking on additional adult roles and decision making. 
The main outcomes of interest included 1) overall attitude toward MEN1 genetic testing 
(P-TAS score) and 2) ideal age to perform genetic testing.  Predictor variables included spouse 
vs. affected patient, demographics, medical history (affected participants only), family history 
characteristics, knowledge of MEN1 genetics, and IES and decisional balance scores.  Most 
demographic data were dichotomized into categorical variables (i.e. residence in the United 
States vs. other, college graduate and above vs. other, income ≤$75,000 vs. >$75,000, etc).  
Age, knowledge, IES scores and decisional balance were analyzed as continuous variables.  
Age was also examined as a dichotomous variable (age younger than 50 years vs. older than 50 
years).  All analyses were performed using Statistical Analysis System (SAS) software (version 
9.2; SAS Institute Inc, Cary, NC).  Pearson’s correlation coefficients were calculated to 
compare responses from affected participants to those of spouses.  Data analysis was performed 
separately for affected participants and partners, as well as for both combined.  For ease of data 
presentation, we report the results from the combined analysis and comment where there were 
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differences when the data was analyzed separately.  For the combined data set, the effect of the 
predictive variables on the two outcomes of interest was examined using generalized linear 
mixed model analyses in order to account for non-independence between patient and spouse. 
When patients and spouses were analyzed separately, a general linear model was used to 
analyze the relationship between predictor variables and P-TAS scores.  A general logistic 
regression analysis was used to evaluate the relationship between the predictor variables and 
ideal testing age.  P-values less than or equal to 0.05 were considered significant.  A 
multivariate model with backward elimination technique using GLIMMIX in SAS was used to 
obtain adjusted odds ratios for ideal testing age and adjusted beta coefficients for overall P-
TAS scores.  Variables that were associated with Ideal Age and P-TAS scores in the univariate 
analysis (p≤0.25) were used as covariates in the multivariate analysis. Characteristics of the 
children were not used in the multivariate analysis due to significant multicollinearity with 
other predictive variables.  Multivariate regression models were used to analyze outcomes in 
parents and spouses separately.  
Additionally, the free response for ideal age were independently coded by two 
reviewers with training in genetic counseling and analyzed to identify common reasons in favor 
or against MEN1 genetic testing in healthy minors.  In many cases, participants had responses 
that could be assigned to more than one category.   
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Results 
 Of the 109 study questionnaires mailed, 10 questionnaires were returned due to 
inaccurate addresses leaving a denominator of 99 affected participants.  It is unclear how many 
people viewed the online advertisement.  A total of 80 participants completed this questionnaire 
through the two recruitment strategies; forty-nine (31 affected participants and 18 partners) 
from MDACC and thirty-one (27 affected participants and 4 partners) from the online 
advertisement. Fifty-eight respondents (73%) had a known mutation in the MEN1 gene whereas 
22 respondents were partners or co-parents of someone with an MEN1 genetic mutation.  
Among the spouses or partners, one (5%) stated they were previously married to someone with 
an MEN1 genetic mutation and one (5%) had either step-children or adopted children at risk of 
developing MEN1.  All other partners were either currently married to someone with MEN1 or 
had biological children at risk of developing MEN1. 
Demographics 
The demographic characteristics of the study population are summarized in Table 1.  
The average age of all respondents was 47.11 years (SD=14.13) with a range of 19 to 76 years.  
The majority of respondents were female (60%) and married (77%).  Fifty-seven percent had 
an education level of college degree or greater with 16% achieving an upper level degree.  
Almost half of participants (49%) were employed full time and 44% had a combined annual 
salary greater than $75,000. Patients recruited online were from several countries around the 
world.  Although all patients recruited from the MDACC database were from the United States, 
A.M.E.N.D is an international support group based out of the United Kingdom and had 
members from many countries.  Fifty-five (69%) participants were from the United States and 
18 (23%) were from the United Kingdom.  Two (3%) respondents were from Canada and there 
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was one (1%) participant from each of the following countries: Germany, Israel, Netherlands, 
New Zealand.   
Table 1. Participants Demographic Characteristics 
Demographics 
 n %  
Affected Participants 58 73%  
Spouses/Partners 22 28%  
Age: Mean (range)               47.11  (19-76) 
 
Gender n % Highest Level of education* n % 
Males 32 40% Some High School 4 5% 
Females 48 60% High School Graduate 5 6% 
Residence* Some College 25 32% 
USA 55 70% College Graduate 25 32% 
Other 24 30% Associate’s Degree 7 9% 
Marital Status* Upper Level Degree 13 16% 
Single 10 13% Occupation* 
Married 61 77% Employed (Full Time) 39 49% 
Separated 2 3% Employed (Part Time) 8 10% 
Divorced 6 8% Unemployed (Not seeking) 4 5% 
Income** Unemployed (Seeking a 
job) 
1 1% 
<$25,000 12 16% Homemaker 11 14% 
$25,000-$50,000 8 11% Student 4 5% 
$50,000-$75,000 18 25% Retired 12 15% 
>$75,000 35 48%  
* 1 respondent did not answer this question 
** 7 respondents did not answer this question 
 
Medical History of Participants with MEN1 
The self-reported medical history of the affected participants is summarized in Table 2.  
Only one participant reported no history of an MEN1-related tumor.  Most (77%) had more 
than one affected gland.  The average age of diagnosis for each tumor, as well as age of MEN1 
diagnosis, was in the late 20s-30s.  The minority (14%) was diagnosed with MEN1 before age 
18 years.   
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Table 2.  Medical History Characteristics for Participants Affected with MEN1 (n = 58) 
Tumor Site N   % Avg. age, years (Range) 
Parathyroid 52 90% 32.39  (11-66) 
Pituitary 22 38% 29.82  (15-57) 
Pancreatic/Gastrointestinal 42 72% 37.00  (10-66) 
 
Metastasized tumor 13 31%  
 
Number of affected sites 
0 1 2%  
1 12 21%  
2 31 53%  
3 14 24%  
 
Avg. Age of MEN1 Diagnosis (range)     33.66  (10-71) 
Diagnosed <18 years 11   14% 
 
Family History 
The MEN1 family history data reported by affected participants and spouses are 
summarized in Table 3.  Most people reported having at least one affected relative (90%) and 
over half (55%) had a relative who had passed away from MEN1-related causes.  Roughly a 
quarter (24%) indicated they had a relative who was diagnosed with MEN1 before the age of 
18 years.  Most (79%) reported that MEN1 had greatly or somewhat greatly affected their 
family’s health and well-being.   
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Table 3. Participants’ Family History of MEN1* 
 n %  n % 
Number of Affected Relatives Experienced an MEN1-related 
Death in a Family Member 
44 55% 
None 8 10% Avg. Age of family 
member’s death (range)            
51.79  
(25-80) 
1-2 28 35%  
3-4 25 32% Had a Relative with an MEN1 
Diagnosis under 18 years   
19 24% 
5 or more 18 23% Avg. age of family member’s 
diagnosis (range) 
14.32 
(10-17) 
 Closest Degree of Relation 
First Degree 9 47% Perceived Severity of MEN1 on Family’s 
Health and Well-Being Second Degree 1 5% 
1 2 3% Third Degree 2 11% 
2 6 8% Unknown 4 21% 
3 16 20%    
4 18 23% Have Children 59 74% 
5 38 48%  
*Includes family history reported by spouses and affected participants 
**1 respondent did not answer this question 
***2 respondents did not respond to this question 
 
Fifty-nine respondents (74%) had at least one child at risk of inheriting MEN1 and 
reported a total of 92 children.  Characteristics of participants with children are described in 
Table 4 and characteristics of the children are described in Table 5.  Sixty-six percent of the 
participants who had children had at least one child who had had genetic testing for MEN1, 
although only 29% had a child affected with MEN1 and only 4 (7%) had a child diagnosed 
before age 18.   The reported children ranged in age from 0-56 (M= 20.57 years; SD=14.82) 
and only 24% had been diagnosed with MEN1.  Of the 66% of the children who had MEN1 
genetic testing, roughly half (52%) were found to be positive.  Age at testing was slightly 
younger than age of diagnosis of an MEN1-related tumor (M=14.82 vs. M=19.89 years).  
Participants were also asked whether or not their children had been told about the MEN1 
diagnosis in the family and 75% responded that they had.   
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Table 4. Characteristics of Participants with Children* 
 n % 
Child <18 years 28 48% 
Child Diagnosed with MEN1 17 29% 
Child Diagnosed with MEN1 < 18 years 4 7% 
Child had genetic testing for MEN1 38 66% 
Child had genetic testing for MEN1 <18 years 21 36% 
Child had a positive genetic test for MEN1 24 41% 
Child told about MEN1 diagnosis <18 years 21 36% 
*Table represents participants who had at least one child in each category. 
 
Table 5.  Characteristics of 92 Children Reported by Participants Affected with 
MEN1 
 
Average Age: 20.567 (0-56) 
Gender n % 
Male 50 54% 
Diagnosis of MEN1-related tumor 
Yes 22 24% 
Avg. Age of diagnosis: 19.889 (3-40) 
Genetic Testing for MEN1 
Yes 61 66% 
Positive 32 52% 
Avg. Age of Testing: 14.820 (0-43) 
Child Told about Family History of MEN1 
Yes 59 75% 
Avg. Age of disclosure 17.587  (3-42) 
 
Knowledge  
 The mean knowledge score was 82.86% (SD=18.38; Table 6).  Thirty-three participants 
(41%) answered all seven questions correctly and 64% scored higher than 75% correct. 
 The knowledge scale initially was designed to include 8 questions, with one that read, 
“A person who carries an altered MEN1 susceptibility gene will definitely develop features of 
MEN1 in his or her lifetime.”  Only 30% of participants selected true for this item and of those 
who responded false, several wrote that it was very likely.  Due to the ambiguous phrasing of 
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the question, this item was dropped from the final analysis as it did not accurately assess the 
participants’ understanding of MEN1 inheritance or natural history. 
Table 6. Responses to Knowledge Questions 
 True False Unsure 
 n % n % n % 
An altered MEN1 susceptibility gene 
can be inherited from either parent. 69 86% 9 11% 2 3% 
If Lisa looks more like her mother 
than her father, she has probably 
received more of her genetic 
information from her mother. 
13 16% 57 71% 10 13% 
Susan is the first born in her family.  
Her mother, who has MEN1, was also 
the first born.  Thus, Susan has a 
higher risk of developing MEN1 than 
her younger brothers and sisters. 
5 6% 66 83% 9 11% 
Rick has had genetic testing for an 
MEN1 gene alteration that was found 
in his family.  His results were 
negative; therefore, he is not at 
increased risk to develop features of 
MEN1. 
65 81% 8 10% 7 9% 
Kelly has had genetic testing for an 
MEN1 gene alteration that was found 
in her family.  Her results were 
negative; therefore, her children are 
not at risk to inherit MEN1 from her. 
54 68% 22 28% 3 4% 
John’s father has an altered MEN1 
gene.  The chance that John has 
inherited this gene alteration is 50% 
or 1 in 2.  
75 95% 0 0% 4 5% 
Once a gene alteration has been 
detected in a person with MEN1, 
their family members can be tested 
for the gene alteration to know for 
certain whether or not they also have 
MEN1. 
78 98% 1 1% 1 1% 
Total Score Avg.:  82.86 (SD=18.382, range=28.571 – 100) 
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Impact of Event Scale 
 Respondents’ mean scores on the Intrusion subscale was 11.21 (SD=8.84, range 0-35).  
Mean score on the Avoidance subscale was 10.93 (SD=8.31, range=0-32).  The overall mean 
IES score was 22.14 (SD=15.58) and ranged from 0 to 58 (maximum possible was 75).   In 
1999, Corneil, et al. [77] categorized IES scores into clinically meaningful ranges of distress.  
In our study, 22 out of 80 participants fell within the subclinical distress range (scores 0-8), 22 
were classified as in the mild range (9-25), 29 were in the moderate range (26-43) and 7 were 
classified as falling within the severe range (44+).  Response rates per question are presented in 
Table 7.  Between affected participants and their partners, Intrusion subscale (r=0.022, 
p=0.935) and total IES (r=0.234, p=0.383) scores were not significantly correlated, but there 
was a significant positive correlation between these groups for the Avoidance subscale mean 
scores (r=0.544, p=0.029). 
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Table 7. Responses to Impact of Event Scale 
 Not at all Rarely Sometimes Often 
 n % n % n % n % 
I thought about it when I didn’t 
mean to. 14 18% 15 19% 33 41% 18 23% 
I avoided letting myself get 
upset when I thought about it 
or was reminded of it. 
12 15% 13 17% 35 45% 18 23% 
I tried to remove it from my 
memory. 36 46% 16 20% 18 23% 9 11% 
I had trouble falling asleep or 
staying asleep because of 
pictures or thoughts about it 
that came into my mind. 
36 45% 23 29% 15 19% 6 8% 
I had waves of strong feelings 
about it. 20 25% 22 28% 27 34% 10 13% 
I had dreams about it. 51 64% 21 26% 6 8% 2 3% 
I stayed away from reminders 
of it. 47 59% 22 28% 8 10% 2 3% 
I felt as if it hadn’t happened to 
me or it wasn’t real. 49 62% 20 25% 8 10% 2 3% 
I tried not to talk about it. 44 55% 10 13% 21 26% 5 6% 
Pictures about it popped into 
my mind. 34 43% 16 20% 21 27% 8 10% 
Other things kept making me 
think about it. 30 38% 19 24% 20 25% 11 14% 
I was aware that I still had a lot 
of feelings about it, but I didn’t 
deal with them. 
36 45% 19 24% 21 26% 4 5% 
I tried not to think about it. 33 42% 13 16% 26 33% 7 9% 
Any reminder brought back 
feelings about it. 31 39% 14 18% 25 31% 10 13% 
My feelings about it were kind 
of numb. 39 49% 13 16% 21 27% 6 8% 
Avg. Total IES:  22.14 (SD=15.58, range=0-58) 
Avg. Intrusion score: 11.21 (SD=8.84, range=0-35) 
Avg. Avoidance score: 10.93 (SD=8.31, range=0-32) 
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Decisional Balance 
 On the decisional balance measure, the mean pros score was 30.17 (SD=4.80) and that 
of cons was 17.55 (SD=5.56).  The mean difference between pros and cons (decisional 
balance) was 12.21 (SD=6.67), and did not differ for affected participants and spouses when 
analyzed separately: (M=12.16, SD=6.77; M=12.34, SD=6.59, respectively).  Although two 
affected participants had a score of 0, no participants had a negative decisional balance score. 
Table 8.  Responses by Question of Decisional Balance 
 Not 
Important 
Slightly 
Important 
Somewhat 
Important 
Importan
t 
Very 
Important 
 n % n % n % n % n % 
I would be 
relieved to know 
my child did not 
have MEN1 
0 0% 3 4% 2 3% 18 23% 55 71% 
My own 
experience with 
MEN1 makes me 
more concerned 
about my child’s 
risk for the 
disease 
2 3% 3 4% 5 6% 23 29% 45 58% 
I’m afraid I would 
get too upset 34 42% 17 22% 15 19% 8 10% 5 6% 
I / My child could 
plan for the future 4 5% 5 6% 6 8% 30 39% 32 42% 
I’m afraid my child 
would get too upset 9 12% 7 9% 30 39% 19 25% 11 14% 
I am concerned that 
having the test 
might cause 
problems with my 
child’s insurance 
14 18% 4 5% 14 18% 13 16% 31 28% 
 
I am concerned 
about my family’s 
 
 
37 
 
 
49% 
 
 
15 
 
 
20% 
 
 
13 
 
 
17% 
 
 
7 
 
 
9% 
 
 
4 
 
 
5% 
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reactions 
I want to learn 
whether my child is 
at risk for MEN1 
0 0% 5 7% 4 5% 17 22% 50 66% 
I am worried about 
how it would affect 
my relationship 
with my child  
35 47% 14 19% 12 16% 7 9% 6 8% 
I’m not sure if the 
genetic test is 
accurate 
32 45% 7 9% 12 17% 11 15% 9 % 
Something could be 
done to improve my 
child’s health 
0 0% 2 3% 5 7% 17 23% 51 68% 
I have a 
responsibility to let 
my child know if 
he/she has MEN1 
2 3% 6 8% 7 9% 19 26% 40 54% 
I just want to know 7 9% 6 8% 14 18% 12 16% 37 49% 
The cost of genetic 
testing is too 
expensive for my 
family to afford 
33 45% 7 9% 16 22% 8 11% 10 14% 
Avg. Sum of Pros: 30.17 (SD=4.80, range=15-35) 
Avg. Sum of Cons: 17.95 (SD=5.56, range=7-34) 
Avg. Decisional Balance: 12.21 (SD=6.67, range=0-28) 
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Pediatric Testing Attitudes Scale (P-TAS) and Correlates 
   The mean score for Factor 1 (Attitudes and Beliefs) on the P-TAS was 25.4 out of a 
maximum of 30 (range 7.2-30; SD= 4.97).  The mean score for Factor 2 (Decision Making and 
Communication) was 19.0 out of a maximum of 25 (range 11-25; SD= 3.09) The mean total P-
TAS score was 44.40 out of a maximum of 55 (range 19.2-55; SD=7.22).  Responses between 
affected participants and partners were not correlated (Factor1: r=0.35, p=.20; Factor 2: r=0.25, 
p=.362; Total: r=0.33, p=.225). 
Table 9.  Responses to P-TAS questionnaire 
 Strongly 
Disagree Disagree 
Neither 
Agree nor 
Disagree 
Agree Strongly Agree 
 n % n % N % N % n % 
Children under age 18 
should be given the 
opportunity to be 
genetically tested for 
the MEN1gene 
alteration 
2 3% 2 3% 6 8% 28 35% 41 52% 
Parents should decide if 
their children are 
allowed to have an 
MEN1 genetic test or 
not, even if a doctor 
disagrees 
3 4% 6 8% 11 14% 27 35% 30 39% 
Even though some of 
the conditions 
associated with MEN1 
may not affect people 
until they reach 
adulthood, children 
should still be offered 
MEN1 genetic testing 
2 3% 1 1% 4 5% 30 38% 42 53% 
Children should be 
involved in making the 
decision about whether 
or not they have MEN1 
genetic testing 
4 5% 10 13% 16 20% 32 41% 16 21% 
I am in favor of MEN1 2 3% 2 3% 8 10% 26 33% 40 51% 
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genetic testing for 
children 
If children are tested 
and they turn out to 
carry an MEN1 gene 
alteration (that is, they 
test positive), they 
should be told about 
their test result 
immediately 
4 5% 23 29% 17 22% 21 27% 14 18% 
 
Even if there is no 
known prevention for 
the conditions 
associated with MEN1, 
children should be 
offered MEN1 genetic 
testing 
 
1 
 
1% 
 
3 
 
4% 
 
7 
 
9% 
 
29 
 
37% 
 
39 
 
49% 
If children are tested 
and they turn out to 
carry a MEN1 gene 
alteration (that is, they 
test positive), then this 
information should be 
shared with the child’s 
pediatrician 
0 0% 2 3% 8 10% 32 41% 37 46% 
I want my child to have 
genetic testing for 
MEN1 before age 18 
1 1% 2 3% 20 27% 18 24% 33 45% 
If children are tested 
and they turn out not to 
carry an MEN1 gene 
alteration (that is, they 
test negative), they 
should be told about 
their test result 
immediately 
2 3% 10 13% 13 16% 26 33% 28 35% 
The benefits of children 
participating in MEN1 
genetic testing 
outweigh the risks 
1 1% 4 5% 15 19% 19 25% 38 49% 
Total Summed Avg.: 44.40 (SD=7.22, range=19.2-55) 
Attitudes and Beliefs: 25.43 (SD=4.97, range=7.2-30) 
Decision Making and Communication: 18.97 (SD=3.09, range= 11-25) 
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Results from the univariate generalized linear mixed model regression analysis of the 
association between independent variables and subscale and overall P-TAS scores are 
summarized in Table 10. Younger current age predicted higher P-TAS scores (β = -0.147, p = 
0.03) and appeared to be primarily driven by the respondents’ Factor 1 scores, rather than 
Factor 2 scores.  Knowledge scores were positively associated with P-TAS scores, (β = 1.789. 
p=0.012), although this association did not reach levels of statistical significance for spouses 
alone (p=0.228).   For family history, P-TAS scores were higher among participants who had 
more than two relatives affected with MEN1 (β = 3.444, p=0.050).  However, the number of 
relatives diagnosed before age 18, the number of relatives who have had an MEN1-related 
death, the overall perceived disease severity, and characteristics of participants’ children were 
not associated with overall P-TAS scores.  Having at least one child who had genetic testing, 
regardless of the result or age of testing, was associated with higher Factor 2 (Decision-Making 
and Communication) scores (β = 0.871, p = 0.032). 
Decisional balance scores also were positively associated with both P-TAS factor 
scores, as well as overall P-TAS score (β = 0.36, p<0.0001).  There also was a positive 
association between the mean pros and P-TAS scores for both factors and total P-TAS 
(p=<0.0001) suggesting that scores of the pros are the driving factor in the decisional balance 
with regard to opinions about genetic testing. 
P-TAS scores between affected participants and spouses were not significantly 
different.  Personal medical history was also not associated with higher P-TAS scores, nor was 
the number of affected sites.  Age of diagnosis trended towards a negative association with 
Factor 1 scores (p=0.061), but was not associated with overall P-TAS scores. 
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Multivariate analysis for P-TAS scores included the covariates current age, marital 
status, highest level of education completed, number of affected relatives, and decisional 
balance (Table 11).  This model showed that a positive association between decisional balance 
and overall P-TAS scores remained statistically significant (p= 0.0002) while number of 
affected relatives was not (p= 0.07).  Additionally, current age was no longer found to be 
significant. 
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Table 10.  Generalized Linear Mixed Model for Predictors of P-TAS Scores for All 
Respondents 
 n Attitudes and 
Beliefs  
(Factor 1) 
Decision Making 
and Communication 
(Factor 2) 
Total PTAS 
Demographic 
and Medical 
History 
 Beta 
(SE) 
p-value Beta 
(SE) 
p-value Beta 
(SE) 
p-value 
Affected 
participants 
57 
Partners 22 
0.406 
(1.157) 
0.731 0.947 
(0.731) 
0.216 1.444 
(1.658) 
0.399 
Age  -0.126 
(0.039) 
0.006 -0.019 
(0.026) 
0.460 -0.147 
(0.058) 
0.0248 
Knowledge  1.043 
(0.432) 
0.030 0.741 
(0.265) 
0.014 1.789 
(0.619) 
0.012 
Decisional 
Balance 
 0.264 
(0.036) 
<0.001 0.091 
(0.027) 
0.005 0.357 
(0.055) 
<0.001 
Impact of Event  -0.029 
(0.036) 
0.432 0.017 
(0.023) 
0.454 -0.066 
(0.093) 
0.488 
Intrusion  0.014 
(0.064) 
0.825 0.052 
(0.039) 
0.208 0.066 
(0.093) 
0.488 
Avoidance  -0.123 
(0.064) 
0.092 0.002 
(0.043) 
0.967 -0.121 
(0.100) 
0.244 
Number of 
affected relatives 
 2.134 
(1.110) 
0.075 1.170 
(0.700) 
0.117 3.444 
(1.605) 
0.050 
≤2 35       
>2 48       
Age of 
Diagnosis* 
 -0.077 
(0.040) 
0.061 -0.007 
(0.027) 
0.798 -0.084 
(0.061) 
0.175 
Children  1.462 
(1.306) 
0.282 0.309 
(0.813) 
0.710 1.782 
(1.903) 
0.365 
Yes 59       
No 20       
Child with 
Genetic Testing 
 1.555 
(1.202) 
0.218 2.089 
(0.871) 
0.032 3.567 
(1.814) 
0.071 
Yes 38       
No 20       
Child tested 
before 18 years 
 2.888 
(1.345) 
0.069 -0.297 
(1.127) 
0.800 2.854 
(2.219) 
0.240 
Yes 21       
No 13       
* Calculated for affected participants only using a general linear model. 
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Table 11. Multivariate Analysis of Predictors for Total P-TAS Scores 
 Adjusted-Beta (SE) p-value 
Current Age -0.076 (0.054) 0.188 
Married/Long-term Partner 2.408 (1.707) 0.186 
College Graduate or higher -2.461 (1.375) 0.101 
Greater than 2 affected 
relatives 
2.700 (1.344) 0.070 
Decisional Balance 0.320 (0.057) 0.0002 
 
Ideal Age for Genetic Testing 
Overall, 44 participants felt the ideal age for genetic testing for MEN1 should be 
younger than 14 years and 18 participants felt the ideal age for testing was older than 14 years. 
Eighteen participants did not respond or provided answers that could not be coded as younger 
than or older than 14 and were not included in the analyses. 
  Older participants were more likely to favor testing over the age of 14 (p=0.026).  When 
current age was dichotomized between younger than and older than 50 years, the odds of a 
participant over 50 years favoring genetic testing after age 14 was 5.33 times higher compared 
to those under the age of 50 (p=0.025). 
 Participants who had a lower mean decisional balance score were more likely to support 
testing at ages older than 14 (p=0.0267).  Similar responses were seen in partners alone 
(p=0.039) and responses for affected participants followed a similar yet not significant trend 
(p=0.060).  Overall, participants whose mean pros scores were lower were more likely to select 
an age greater than 14 for genetic testing (p=0.027).   
Among affected participants only, those with higher mean knowledge scores favored 
genetic testing before age 14 compared with patients with lower mean knowledge scores 
(p=0.034).  A similar positive trend was also found for the combined dataset (p=0.0523) 
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The majority of affected participants (73%) favored genetic testing in children under the 
age of 14 years.  Similarly, 65% of partners favored genetic testing before age 14 years.  
However, no statistically significant difference was noted between affected participants and 
partners with regard to their preference in age for predictive genetic testing.  Demographic 
characteristics including gender, country of residence, marital status, education, employment 
and income also were not associated with preferred age of testing, nor were personal medical 
history, including number of affected glands or age of diagnosis, and family history 
characteristics. 
In a multivariate analysis, none of the covariates including current age, highest level of 
education completed, knowledge, intrusion scores and decisional balance were associated with 
preferred age for testing, possibly due to the limited sample size.  In a separate multivariate 
logistic regression model including affected participants only, adjusted OR suggest that having 
an education level of college graduate or higher and being employed were associated with 
favoring genetic testing after age 14 (p=0.043 and p=0.048 respectively), whereas higher 
knowledge scores were associated with favoring genetic testing in children younger than 14 
years (p=0.008). 
Children’s wellbeing, genetic testing, and knowledge of MEN1 in the family also were 
analyzed as predictor variables for respondents with children.  None of these predictors reached 
levels of statistical significance.  However, the variable most closely approaching levels of 
statistical significance was whether or not a child had been diagnosed with MEN1, regardless 
of age (p=0.061). Respondents who do not have a child diagnosed with MEN1 were more in 
favor of testing children before age 14 years.  When affected participants were analyzed 
separately, they were 6.25 times more likely to support genetic testing in children over the age 
of 14 if they had a child that was diagnosed with MEN1 (p=0.034).  
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Table 12. Generalized Linear Mixed Model for Continuous Predictors of Ideal Age for All 
Participants 
Demographics and Medical 
History 
% Ideal 
Age ≤14 
years 
% Ideal 
Age >14 
years 
OR (95% CI) p-
value 
Affected Participants 33 12 0.647 
(0.144-2.901) 
0.528 
Partners 11 6   
Current Age      
<50 years 31 5 6.484 
(1.338-31.429) 
0.025 
≥50 years 11 6   
Child Diagnosed with MEN1   5.956 
(0.900-39.422) 
0.061 
Yes 6 8   
No 27 6   
 
Table 13. Generalized Linear Mixed Model for Dichotomous Predictors of Ideal Age for 
All Participants 
Demographic and 
Medical History 
OR (95% CI) P 
Age 1.070 
(1.010-1.133) 
0.026 
Knowledge 0.572 
(0.325-1.007) 
0.053 
Decisional Balance 0.572 
(0.854-0.988) 
0.027 
Sum of Pros 0.0899 
(0.821-0.985) 
0.027 
Sum of Cons 1.028 
(0.955-1.108) 
0.415 
Impact of Event 0.977 
(0.930-1.027) 
0.322 
Intrusion 0.925 
(0.841-1.017) 
0.097 
Avoidance 1.003 
(0.915-1.100) 
0.936 
Age of Diagnosis* 1.037 
(0.992-1.083) 
0.109 
* Calculated for affected participants only using logistic regression analysis. 
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Table 14.  Multivariate analysis for Predictors of Ideal Age (combined data) 
 Adjusted OR 
(95% CI interval) 
P 
Age 1.065 
(0.981-1.155) 
0.105 
College graduate and above 5.441 
(0.395-74.88) 
0.157 
Knowledge 0.534  
(0.202-1.412) 
0.158 
Intrusion 0.906 
(0.766-1.073) 
0.195 
Decisional Balance 0.936 
(0.847-1.035) 
0.1522 
 
 
Table 15.  Multivariate Analysis for Predictors of Ideal Age (affected participant 
only) 
 Adjusted OR 
(95% CI interval) 
P 
College graduate and above 15.56 
(1.087-222.746) 
0.043 
Employed (full time/part 
time) 
49.974 
(1.03->999.99) 
0.048 
Knowledge 0.141 
(0.033-0.595) 
0.008 
Age of Diagnosis 1.09 
(0.996-1.192) 
0.060 
  
Reasons for Testing 
 Multiple reasons were identified for selecting specific ages and participants frequently 
gave more than once answer.  Nine themes were identified in favor of testing and two were 
identified against testing.  The first theme, “old enough to understand and participate in 
decision-making,” was the most common response (41%) and included answers such as “Old 
enough to understand the ramifications/consequences,” and “Would want the ability to make an 
informed decision and to be able to manage the consequences mentally and physically.”  The 
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second most common theme was to allow for earlier monitoring of symptoms and tumor 
markers (14%) and for increased knowledge and planning (14%), including educating local 
physicians and planning for an appropriate time for treatment.  The theme “personal and family 
experience” (11%) included respondents who selected an age based on when signs of MEN1 
first began in their family. Several respondents (6%) who selected a younger age for testing did 
so to allow the child to accept the diagnosis as part of their normal life, while another 6% who 
selected older ages acknowledged the benefits of family planning with a diagnosis.  Five 
percent felt genetic testing should be done early because symptoms have been reported in very 
young children. Three percent of respondents identified psychological benefits from predictive 
testing, such as reassurance from a negative test result.  Only two respondents (3%) stated they 
selected an ideal age based on local physician recommendations.  Several participants 
identified negative outcomes of genetic testing as reasons for delaying or never having genetic 
testing.  These included psychological concerns at a young age when there is little or no risk 
(6%) and fears about insurance discrimination (5%).  Although all of these reasons were 
selected by multiple participants, they were often identified at different times in a child’s life.  
Figure 1 shows the distribution of reasons for and against genetic testing at various points in a 
child’s life. 
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Table 16.  Reasons for and Against Genetic Testing* 
Reasons for genetic testing  
Old enough to understand and participate in decision 
making 
41% 
Earlier monitoring 14% 
Allows for increased knowledge and planning 14% 
Based on personal or family experience with MEN1 11% 
Family Planning 6% 
Easier to accept as part of normal life 6% 
Could happen at any age 5% 
Psychological Benefits 3% 
Local recommendations 3% 
Reasons against genetic testing  
Psychological Concerns 6% 
Avoid insurance discrimination 5% 
*Answers are not mutually exclusive 
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Figure 1.  Distribution of Reasons for and Against Genetic Testing Across Age Groups 
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Discussion 
 Most published literature about genetic testing in minors are expert opinions from 
ethicists and although opinions about predictive genetic have been studied in a few other 
genetic syndromes [59] [60] [62] [64] [66], no studies have examined this question specifically 
in MEN1.  This study sought to determine the attitudes about predictive MEN1 genetic testing 
in those at risk of having a child with MEN1.  This study was exploratory in nature and opens 
up several possibilities for future studies and avenues for genetic counseling. 
Overall, participants in this study seem to favor genetic testing in minors.  Of those who 
gave specific ages or age ranges, only seven favored delaying testing until after age 18.   The P-
TAS is a relatively new scale that was previously validated in a population at high risk for a 
BRCA mutation [76].  Participants in our study had higher scores for each factor and for total 
P-TAS scores than participants in this original study.  This is most likely attributable to the 
later age of onset of BRCA-related cancers, which almost never present in minors.   The fact 
that participants have relatively high P-TAS scores demonstrates that both affected participants 
and their partners have opinions about genetic testing more similar to a young onset condition 
instead of an adult onset condition. 
Respondents’ age at the time of study completion was found to be a predictor for 
attitudes about genetic testing in most of the completed analyses with older participants more 
likely to favor postponing genetic testing until children are older.  Older patients may be more 
likely to have experienced the effects of MEN1 for longer periods of time either in themselves 
or in their families.  They may also be more aware of the long-term psychological effects that 
come from aging with MEN1, having been diagnosed and adjusted to the diagnosis themselves.  
Prior to the availability of MEN1 genetic testing, diagnoses were made on a clinical basis.  
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With advances in genetic technology, this younger generation of at risk individuals will be the 
first to have predictive testing available to them.  Therefore, older participants may also be 
drawing on their own experiences with genetic testing when considering the most appropriate 
age for predictive testing.  It is also likely that younger participants may have benefitted from 
earlier genetic testing and/or medical surveillance than older participants, and this might be 
influencing their opinions about the ideal age to have genetic testing.  
 Reasons given for genetic testing at an older age seemed to be strongly focused on 
psychological reasons, including the age at which the child can understand and participate, 
knowledge and planning, and family planning.  On the other hand, many participants who 
favored younger ages for testing, including at birth, early childhood and childhood, found the 
perceived medical benefits of testing to be the predominant factor in their decision making 
about the ideal age to test, which is consistent with previous findings in the literature [52] [53] 
[54] [55].  A second predictor, knowledge of MEN1 genetics, suggests that patients with a 
better understanding of MEN1 favor genetic testing in minors.  This may also suggest that 
patients with increased knowledge scores may be more focused on these medical effects and 
the opportunity for increased screening over the psychological concerns.   
A third predictor for opinions about genetic testing was the number of affected relatives 
in a family.  Participants with two or more affected relatives were also more likely to favor 
genetic testing in minors.  Although this variable fell out of significance during the multivariate 
analysis, it does point towards a possible trend in family history and suggests that increased 
exposure throughout a family may be contributing to opinions favoring a younger age for 
genetic testing.  Because no other family history variables were found to be significant 
predictors, this is an area that may benefit from future research specifically focused on the 
impact of family history on age of genetic testing. 
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Finally, decisional balance was consistently found to be a strong predictor of 
preferences for genetic testing at a younger age. As part of the transtheoretical model, the 
decisional balances aims to place participants along a spectrum of stage of change related to a 
health behavior, in this case genetic testing in minors.  Participants who perceive the cons as 
outweighing the pros are less likely to have achieved the action stage of state of change [78]. It 
would be expected that parents who place a greater emphasis on the positives of genetic testing 
would be more likely to favor genetic testing in minors and/or pursue genetic testing in their 
own children, if possible.  In fact, participants in this study seemed to have predominantly 
positive attitudes about genetic testing with a positive association towards testing in minors and 
ideal age less than 14 years. Additionally, a trend appears to be emerging between participants 
who have had a child tested for MEN1 and overall P-TAS scores.  This might indicate that 
participants who are in favor of genetic testing in minors are truly having their child tested for 
MEN1 or encouraging their adult children to do so. 
Interestingly, this study also identified several factors that do not predict opinions about 
genetic testing.  Personal medical history does not have a significant impact on opinions about 
testing.  The reported MEN1-specific medical history of this study population is typical of 
individuals with MEN1 reported in the literature, including tumor prevalence and age of 
diagnosis [1] [5] [6] [38].  The high penetrance of MEN1-related tumors is also evident given 
that all but one affected participants reported a history of at least one tumor type.  No clear 
pattern emerged between personal medical factors and attitudes for genetic testing suggesting 
that opinions vary across patients with MEN1 diagnosed at all ages and with differing degrees 
of severity. 
Additionally, MEN1-related stress (measured with the Impact of Event scale and 
perceived severity of disease) does not appear to impact opinions about predictive MEN1 
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genetic testing.  Although responses appeared to suggest high levels of MEN1-related stress 
with nearly half of participants scoring in the moderate to severe range for IES and most 
patients selecting “greatly” for perceived disease severity in the family, neither appeared to 
predict attitudes about predictive genetic testing in minors. Several studies have examined 
levels of stress and anxiety and the resulting willingness to seek out medical treatment or 
genetic testing.   Many have shown that patients with high levels of anxiety often seek out 
frequent medical advice and reassurance [79] [80].  However, other studies have suggested that 
those at a highest risk or who have already begun to show symptoms are also likely to avoid 
medical care or postpone presenting to a doctor for fear of the emotional repercussions of a 
diagnosis or genetic testing [81] [82].  Therefore, it is possible that patients with higher IES 
scores and perceived severity may act in either way with regards to seeking out genetic testing 
for themselves or their children. 
As an exploratory study, it is particularly interesting to note the reasons that participants 
provided for selecting specific ideal ages for MEN1 genetic testing.  With certain exceptions, 
psychological effects seem to be a driving factor in choosing later ages for genetic testing, 
while perceived medical benefits seem to be driving factors at a younger age. A handful of 
patients selected multiple ages that often varied significantly.  For example, one participant 
selected ages 10-12 based on the medical effect it can have during the teenage years but also 
selected 25 years and older because of the potential difficulty of obtaining health insurance.  
These varied responses further emphasize the lack of clear consensus for when testing should 
be performed and also highlight the idea that patients views may be highly conflicted. 
Several of the reasons provided in response to this questionnaire matched opinions and 
concerns expressed in the literature.  The most common reason cited was an age at which 
children can understand the implications of genetic testing. This is a sentiment that mirrors 
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opinions in professional statements about genetic testing in minors for conditions of unknown 
significance, which emphasize the importance of involving the child and family in the decision 
making process [50] [51].  Several authors who support testing at a young age indicated that it 
would give the child time to accept the diagnosis and adjust to it being part of their everyday 
life [54].  This sentiment was echoed by roughly 6% of participants in this study. Other 
responses pointed out the enormous psychological burden that could be placed on a child if the 
test was positive, years before they may begin to show symptoms.  This concern has also been 
addressed by authors exploring the potential impacts on children [52] [53] [57].  Thus, this 
study exemplifies the varying opinions about the psychological impact of genetic testing and 
adds data to the ongoing debate about the psychological effects of genetic testing in minors. 
Only two participants selected local physician recommendations as their reason for the 
most appropriate age for genetic testing.  Of those who selected local recommendations as a 
reason for genetic testing, one selected age 5 while the other selected age 10. This again 
underscores the lack of a clear consensus about the appropriate age for testing.  However, the 
low identification with this reason also demonstrates that what guidelines do exist are either not 
being expressed to patients and their families, or that patients are forming their own opinions 
based on additional factors and their own experiences with MEN1.   
Fear of insurance discrimination was listed as a major reason against genetic testing, 
however only cited by a minority of participants. Interestingly, many of the participants who 
cited this reason were from the UK and stated that it wasn’t a concern within the UK, but it 
would be if they lived in a country without universal healthcare.  Unlike the US, the UK has a 
universal health care system funded by the National Health Service (NHS).  Health insurance is 
guaranteed to every citizen to cover medical care from primary physicians as well as 
specialists. However many citizens also opt to purchase private medical insurance[83].  In 
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2009, the Genetic Information Non-discrimination Act [84] was enacted in the United States 
and prohibits health insurance companies and employers from discriminating or denying 
coverage based on the results of a genetic test. However, this act does not extend to life 
insurance or long-term disability insurance.  The possibility of genetic discrimination is less 
significant in countries with a universal health care system.  Although there is currently no law 
in the United Kingdom that mirrors GINA, several interest groups have been created to monitor 
the progression of genetic testing and its impact on health insurance.  A set of moratoriums 
have been put in place that prohibit insurance companies from raising premiums based on 
genetic test results [83].  Concern about insurance discrimination has frequently been cited by 
patients as a limitation for genetic testing in general [85] [86] and many participants in this 
study were likely tested prior to the initiation of any protective laws, particularly in the United 
States.  It is unclear to what extent the study participants knew about anti-genetic 
discrimination laws.  It may be that some individuals would be reassured if they knew about 
laws such as GINA which could change their opinion about genetic testing.  Indeed, several 
individuals had stated that they were not sure if any anti-discrimination laws had been passed. 
Alternately, it may be that people are not reassured that GINA will actually help to protect 
them and their family members.  With the implementation of these laws and other protective 
measures, it will be interesting to monitor the uptake of genetic testing and see if it alters 
opinions about genetic testing in minors. 
Strengths of Study 
 Very few studies have investigated the psychological state of patients with MEN1. This 
study is the first of its kind to investigate opinions about predictive genetic testing in minors.  
Considering the rarity of MEN1, this was a large sample size that included opinions from 
around the world.  This allowed for opinions from various backgrounds and multiple health 
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care systems.  Additionally, a strength of this study is that it looked directly at the opinions of 
those at risk of having a child with MEN1 and incorporates responses from both affected 
participants and co-parents. 
Another strength of this study is that most measures used are validated survey tools.  
The Impact of Event scale is a frequently used measure for post-traumatic stress disorder and 
the decisional balance has been used to measure stage of change.  The Pediatric Testing 
Attitudes Scale is a relatively new measure that is expected to be used more often in future 
studies about genetic testing in minors.  The use of validated study measures in this study 
strengthens confidence in the results. 
Limitations and Future Studies 
 The major limitation of this study is that it was a self-administered questionnaire.  As 
such, all medical and family data were self-reported and could not be verified, and the accuracy 
of the diagnosis of MEN1 could not be assessed in participants recruited from the Internet.  
However, in reviewing the reported medical histories, all participants were typical of MEN1 
patients reported in the literature.  Additionally, participants were given the option to skip any 
questions with which they were uncomfortable, resulting in missing data.  Our study was 
administered to any patient with a positive genetic test result and their spouses or long-term 
partners.  This sample included both patients with and without children.  Therefore, some 
patients were asked to imagine how they would feel about their hypothetical children, which 
can be difficult for some patients to consider. 
 Although our sample size was large for the condition, it was still a small sample size 
from a statistical perspective.  Clear trends were evident in the data analysis; but future studies 
may be able to elucidate further patterns related to a participant’s opinions about predictive 
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genetic testing.  Because patients and spouses may have some correlation, a generalized linear 
mixed model was used for data analysis.  However, it is reasonable to assume that spouses may 
have an influence on each other’s opinions that could not be captured in the data analysis. 
 As understanding of MEN1 and cancer genetics continues to grow and screening 
technologies improve, it will be important to continually reconsider the most appropriate age 
for MEN1 genetic testing.  Currently, data into the psychological impact of MEN1 is lacking 
and further studies may help to elucidate the most important issues for patients living with 
MEN1.  Further studies investigating the opinions of health care professionals and how they 
counsel families about predictive genetic testing may help to improve guidelines for the most 
appropriate age for genetic testing.  Studies about patients who have had predictive genetic 
testing themselves may also shed more light on the long-term psychosocial effects, as this will 
likely be the first generation to have access to predictive genetic testing. 
Conclusions and Implications 
Our initial hypotheses were that there would be a significant difference between 
affected participants and spouses and that age of diagnosis would have an impact on the 
preferred age of predictive testing.  While we did not find either of these to be true, we did find 
several interesting trends.  The most significant predictors of favoring genetic testing in minors 
are younger current age, increased knowledge, two or more affected relatives, and a positive 
decisional balance.  Overall, it was clear that most patients and their spouses felt that MEN1 
should be addressed earlier than adult-onset conditions and rather as a syndrome with unknown 
medical significance at a younger age.  Specific considerations for testing in younger children 
focused primarily on the perceived medical benefits, whereas participants who selected older 
ages in minors were focused primarily on the psychosocial impacts of genetic testing.  These 
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findings will have several implications for genetic counseling for families at risk of having a 
child with MEN1.  Although this study was not able to elucidate a single age at which genetic 
testing would be most appropriate, the results of this study may help patients consider multiple 
viewpoints which may help them determine which factors are most important to them and their 
families.  When discussing genetic testing with patients, it may also be worthwhile to discuss 
reasons other families have expressed for pursuing genetic testing in children. Among the 
various responses given, many participants expressed that it was an individual decision for each 
child and parent involved.  Therefore, in selecting the most appropriate age for their child to be 
tested, parents will likely have the clearest ideas about when their child will be able to 
understand and deal with the results of a positive genetic test.   
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APPENDIX A. INVITATION LETTER 
Clinical Cancer Genetics Program 
T 713-563-1908  F 713-745-1921 
Unit 444 
1400 Hermann Pressler Dr 
Houston, TX 77030-4008 
 
Date: December 7, 2011 
Name:  
Address: 
Dear Ms./ Mr. <Name>: 
We are writing to thank you for your continued participation in our research involving MEN1 
and to let you know about a new opportunity.  We would like to invite you to take part in a 
research study entitled Parental Attitudes of Predictive MEN1 Genetic Testing in Minors.  We 
are interested in learning about your experiences and feelings towards MEN1 genetic testing 
in healthy children.   
We are inviting you to participate because you, your spouse/partner, or a family member was 
seen for MEN1 at M. D. Anderson Cancer Center.  As you know, MEN1 is a rare hereditary 
condition that increases cancer risk and can be passed on to children.  The ideal age for 
genetic testing in minors who have no symptoms is unclear.  We are interested in learning how 
families with MEN1 feel about having their children genetically tested for MEN1.  Participation 
in this research study is voluntary and involves completing the enclosed survey.  The survey 
should take about 15-20 minutes to complete and there is no cost to participate.   
Although your participation in this project may not have direct benefit to you, it will help 
researchers, doctors and genetic counselors better understand the needs of families with 
children at risk for MEN1. Some of the questions may be upsetting and you do not have to 
answer them.  If you decide to participate in the study, it is very important that you answer as 
completely as you can; please feel free to add comments or questions on the survey and we 
will do our best to respond. 
If you would like to participate in this study, please complete the questionnaire that is included 
in this packet and return it to us in the pre-paid addressed envelope.  Patients who have been 
diagnosed with MEN1, please complete the white survey.  Spouses or partners of persons 
with MEN1 please complete the yellow survey.   We are interested in responses from both 
patients and spouses but responses will still be included even if only one person is available to 
participate.  
If you prefer the online survey, please go to http://www.surveymonkey.com/s/MEN1inminors 
and follow the instructions.  You will need to enter your ID user number, which is <insert ID #>.  
The online survey has the same questions as the one included in this packet and was created 
using a professional account on Survey Monkey, which is a confidential survey making tool.  
Your responses will be strictly confidential and will only be shared with study staff.   
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Clinical Cancer Genetics Program 
T 713-563-1908  F 713-745-1921 
Unit 444 
1400 Hermann Pressler Dr 
Houston, TX 77030-4008 
 
At the end of the survey, there is a place to write your name and telephone number if you 
are willing to be contacted with questions about any of your responses.  If you have any 
friends or relatives you think would be interested in participating in the study, a space is 
available for their contact information so we can send them a copy of this letter as well.  
Providing contact information is optional, and your name will not be linked with your survey 
responses, if provided.   
Completion of this survey is optional and confidential.  Due to the anonymous nature of the 
study, questionnaires will not be able to be withdrawn once they have been submitted.  If you 
have any questions or would like more information please contact, the Clinical Cancer 
Genetics Program or your genetic counselor at (713) 745-7391 or e-mail 
ccg@mdanderson.org. 
Thank you very much for considering this invitation to participate in our study. 
Sincerely, 
 
Katie Rock, BA  Thereasa Rich, MS, CGC  Elizabeth Grubbs, MD 
Genetic Counseling Intern Genetic Counselor   Assistant Professor  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APPENDIX B: AFFECTED PARTICIPANT QUESTIONNARIE Please fill out this survey if YOU have been diagnosed with MEN1                               ID# 
I have read the description of the study, and I have decided to participate in the 
research project described here.  I understand that I may refuse to answer any (or all) 
of the questions at this or any time.  I understand that my decision about participating 
in this study or answering questions will not affect the care or services that I receive at 
M. D. Anderson Cancer Center.   
During the course of this study, the research team at The University of Texas M. D. 
Anderson Cancer Center will be collecting information about me that they may share 
with health authorities, study monitors who check the accuracy of the information, and 
individuals who put all the study information together in report form.  Information that 
could identify me personally will not be made public.  By answering the questions, I am 
providing authorization for the research team to use and share my information at any 
time.  If I do not want to authorize the use and disclosure of my information, I may 
choose not to answer these questions.  There is no expiration date for the use of this 
information as stated in this authorization. 
Completion of this survey is optional and confidential.  Due to the anonymous nature 
of the study, questionnaires will not be able to be withdrawn once they have been 
submitted.  If you have any questions or would like more information please contact, 
the Clinical Cancer Genetics Program or your genetic counselor at 713-745-7391 or e-
mail ccg@mdanderson.org.  For information on the Notice of Privacy Practices, please 
call 713-792-2933. 
Attitudes Toward MEN1 Genetic Testing in Minors Survey 
Instructions: We are interested in learning about your attitudes toward MEN1 genetic 
testing for healthy children who are under the age of 18. As you may know, the best 
age for healthy children to undergo MEN1 genetic testing is unknown due to several 
medical, social, and psychological reasons.  We wish to learn about your experience 
and attitudes toward such testing.  
Part 1: The following are questions about YOU. 
1. What is your age: ________ 
 
2. What is your gender?  
 Male    Female 
 
3.  Where do you currently live?    State: ______________  Country:_____________ 
 
4. What is your marital status?  
 Single    Married/Long Term Partner    Separated    Divorced    Widowed 
 
5. What is the highest grade or level of schooling you completed? 
 Some high school   
 High school graduate 
 Some college  
 College graduate (4 Year Degree)  
 Associate’s degree 
 Upper-level degree
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 Please fill out this survey if YOU have been diagnosed with MEN1                               ID# 
6. What is your current occupational status
 
 
7. What is your (combined) annual household income? 
 Less than $25,000  $50,000 - $75,000 
 $25,000 - $50,000  More than $75,000 
 
8. Please check any of the following you’ve been diagnosed with and write the age you were 
diagnosed: 
  Parathyroid gland tumor (hyperparathyroidism); Age diagnosed: _____ 
  Pituitary gland tumor (for example, prolactinoma); Age diagnosed: ____ 
  Pancreatic/stomach/intestinal tumor (for example, gastrinoma, neuroendocrine tumor); 
Age diagnosed: _____ 
Has this tumor spread (metastasized)? Yes      No  
 
9. Have you had genetic testing for MEN1? 
Yes      No  
If yes, was a mutation found (was the test positive)? Yes      No  
 
10. At what age did you first find out you had MEN1 (if you are not sure, just give your best guess)? 
________ 
 
11. How many members of your family also have been diagnosed with MEN1? 
  None 
  1-2 
  3-4 
  5 or more 
 
12. Do you have any relatives who have died from complications of MEN1? 
Yes      No  
If yes, how old were they when they died? __________ 
 
13.  How severely do you feel MEN1 has affected your family’s health and well-being? (Please 
circle a number on the scale below). 
  
Not at all                                      Somewhat                                                  Greatly 
    1        2   3   4   5 
 Employed (Full Time) 
 Employed (Part Time) 
 Unemployed (Not seeking a job) 
 Unemployed (Seeking a job) 
 Homemaker 
 Student 
 Retired 
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 Please fill out this survey if YOU have been diagnosed with MEN1                               ID# 
 
14. Has anyone in your family been diagnosed with an MEN1-related tumor before 18 years of 
age? 
Yes      No   If yes, how old were they? _____ 
If yes, how are they related to you (for example, sister, cousin, etc.)? 
_____ 
 
15. Do you have children? 
  Yes – if yes, please continue to part 2 
  No – if no, please skip part 2, and continue to part 3
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Please fill out this survey if YOU have been diagnosed with MEN1                               ID# 
 
Part 2: Please tell us about each of your children, including your adult children, 
if applicable 
(please only include children who are biologically related to you): 
 
How old 
is this 
child? 
Gender 
Has this child 
been diagnosed 
with any MEN1-
related tumors?  
If yes, how old 
were they when 
they were first 
diagnosed? 
Has this child 
had MEN1 
genetic testing?   
If yes, how old 
were they when 
they were 
tested? 
Have you shared 
your family’s 
diagnosis of 
MEN1 with this 
child?  
If yes, how old 
were they when 
you told them? 
Child 
1  
Male     
Female  
Yes      No     
Age Diagnosed: 
Yes      No     
Age Tested: 
Result: 
Yes      No     
Age Told: 
Child 
2  
Male     
Female  
Yes      No     
Age Diagnosed: 
Yes      No     
Age Tested: 
Result: 
Yes      No     
Age Told: 
Child 
3  
Male     
Female  
Yes      No    
Age Diagnosed: 
Yes      No     
Age Tested: 
Result: 
Yes      No     
Age Told: 
Child 
4  
Male     
Female  
Yes      No    
Age Diagnosed: 
Yes      No     
Age Tested: 
Result: 
Yes      No     
Age Told: 
Child 
5  
Male     
Female  
Yes      No    
Age Diagnosed: 
Yes      No     
Age Tested: 
Result: 
Yes      No     
Age Told: 
Child 
6  
Male     
Female  
Yes      No   
Age Diagnosed: 
Yes      No     
Age Tested: 
Result: 
Yes      No     
Age Told: 
If you have more than 6 children, please use the back of this survey to tell us about 
them. 
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 Please fill out this survey if YOU have been diagnosed with MEN1                               ID# 
Part 3: The following questions are intended to find out what people know about 
cancer and genetic testing so that we can improve our educational efforts.  This 
is not a test.  We are simply interested in finding out what the general level of 
knowledge is regarding these topics.  Please indicate whether you think each 
statement is true or false, or if you don't know. 
16 An altered MEN1 susceptibility gene can be 
inherited from either parent. True False Unsure 
17 
If Lisa looks more like her mother than her 
father, she has probably received more of her 
genetic information from her mother. 
True False Unsure 
18 
A person who carries an altered MEN1 
susceptibility gene will definitely develop 
features of MEN1 in his or her lifetime. 
True False Unsure 
19 
Susan is the first born in her family.  Her 
mother, who has MEN1, was also the first 
born.  Thus, Susan has a higher risk of 
developing MEN1 than her younger brothers 
and sisters. 
True False Unsure 
20 
Rick has had genetic testing for an MEN1 
gene alteration that was found in his family.  
His results were negative; therefore, he is not 
at increased risk to develop features of 
MEN1. 
True False Unsure 
21 
Kelly has had genetic testing for an MEN1 
gene alteration that was found in her family.  
Her results were negative; therefore, her 
children are not at risk to inherit MEN1 from 
her. 
True False Unsure 
22 
John’s father has an altered MEN1 gene.  
The chance that John has inherited this gene 
alteration is 50% or 1 in 2. 
True False Unsure 
23 
Once a gene alteration has been detected in 
a person with MEN1, their family members 
can be tested for the gene alteration to know 
for certain whether or not they also have 
MEN1. 
True False Unsure 
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Please fill out this survey if YOU have been diagnosed with MEN1                               ID# 
Part 4.  Please think about your experience with MEN1 in your family.  Please 
indicate how frequently each comment was true for you during the past seven 
days. 
 
 Not at all Rarely 
Some
times Often 
24 I thought about it when I didn’t mean to. 1 2 3 4 
25 I avoided letting myself get upset when I 
thought about it or was reminded of it. 1 2 3 4 
26 I tried to remove it from my memory. 1 2 3 4 
27 I had trouble falling asleep or staying asleep 
because of pictures or thoughts about it that 
came into my mind. 
1 2 3 4 
28 I had waves of strong feelings about it. 1 2 3 4 
29 I had dreams about it. 1 2 3 4 
30 I stayed away from reminders of it. 1 2 3 4 
31 I felt as if it hadn’t happened to me or it wasn’t 
real. 1 2 3 4 
32 I tried not to talk about it. 1 2 3 4 
33 Pictures about it popped into my mind. 1 2 3 4 
34 Other things kept making me think about it. 1 2 3 4 
35 I was aware that I still had a lot of feelings 
about it, but I didn’t deal with them. 1 2 3 4 
36 I tried not to think about it. 1 2 3 4 
37 Any reminder brought back feelings about it. 1 2 3 4 
38 My feelings about it were kind of numb. 1 2 3 4 
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Please fill out this survey if YOU have been diagnosed with MEN1                               ID# 
Part 5: The following questions ask about your personal feelings about genetic 
testing in healthy minors (in other words, individuals with no medical conditions 
who are younger than age 18).  Please indicate your agreement with each of the 
following statements using the scale below. 
 Strongly 
Disagree 
Disagree Neither 
Agree 
nor 
Disagree 
Agree Strongly 
Agree 
39 
Children under age 18 
should be given the 
opportunity to be genetically 
tested for the MEN1gene 
alteration  
1 2 3 4 5 
40 
Parents should decide if 
their children are allowed to 
have an MEN1 genetic test 
or not, even if a doctor 
disagrees 
1 2 3 4 5 
41 
Even though some of the 
conditions associated with 
MEN1 may not affect 
people until they reach 
adulthood, children should 
still be offered MEN1 
genetic testing 
1 2 3 4 5 
42 
Children should be involved 
in making the decision 
about whether or not they 
have MEN1 genetic testing 
1 2 3 4 5 
43 I am in favor of MEN1 genetic testing for children 1 2 3 4 5 
44 
If children are tested and 
they turn out to carry an 
MEN1 gene alteration (that 
is, they test positive), they 
should be told about their 
test result immediately 
1 2 3 4 5 
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45 
Even if there is no known 
prevention for the 
conditions associated with 
MEN1, children should be 
offered MEN1 genetic 
testing 
1 2 3 4 5 
46 
If children are tested and 
they turn out to carry a 
MEN1 gene alteration (that 
is, they test positive), then 
this information should be 
shared with the child’s 
pediatrician 
1 2 3 4 5 
47 
I want my child to have 
genetic testing for MEN1 
before age 18 
1 2 3 4 5 
48 
If children are tested and 
they turn out not to carry an 
MEN1 gene alteration (that 
is, they test negative), they 
should be told about their 
test result immediately 
1 2 3 4 5 
49 
The benefits of children 
participating in MEN1 
genetic testing outweigh the 
risks 
1 2 3 4 5 
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Please 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this 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if 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have been diagnosed with 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Part 6: The following list includes reasons some people give for wanting or not wanting to 
have their child have genetic testing.  Please indicate how important you feel each of the 
following is in making a decision to have MEN1 genetic testing for your child using the 1-5 
point scale.  
 
Not 
Importa
nt 
Slightly 
Importa
nt 
Somewh
at 
Important 
Impor
tant 
Very 
Importa
nt 
50 I would be relieved to know my child did not have MEN1 1 2 3 4 5 
51 
My own experience with MEN1 makes 
me more concerned about my child’s 
risk for the disease 
1 2 3 4 5 
52 I’m afraid I would get too upset 1 2 3 4 5 
53 I / My child could plan for the future 1 2 3 4 5 
54 I’m afraid my child would get too upset 1 2 3 4 5 
55 
I am concerned that having the test 
might cause problems with my child’s 
insurance 
1 2 3 4 5 
56 I am concerned about my family’s 
reactions 1 2 3 4 5 
57 I want to learn whether my child is at 
risk for MEN1 1 2 3 4 5 
58 I am worried about how it would affect 
my relationship with my child  1 2 3 4 5 
59 I’m not sure if the genetic test is 
accurate 1 2 3 4 5 
60 Something could be done to improve 
my child’s health 1 2 3 4 5 
61 I have a responsibility to let my child 
know if he/she has MEN1 1 2 3 4 5 
62 I just want to know 1 2 3 4 5 
63 The cost of genetic testing is too expensive for my family to afford 1 2 3 4 5  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Please fill out this survey if YOU have been diagnosed with MEN1                               ID# 
64.  What do you feel is the ideal age for an individual to have MEN1 genetic testing? Why 
did you choose this age?  
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 Please fill out this survey if YOU have been diagnosed with MEN1                               ID# 
The following questions are optional: 
Please indicate if we may contact you by phone with any follow up questions:  
 Yes  No 
 Name: __________________________________ 
 Phone Number: __________________________ 
 
We would like to include as many people as possible in this survey.  Individuals with 
MEN1 and their spouses/partners are eligible.  Please tell us about any friends or 
relatives who may be interested in participating in our study: 
 Name: _____________________________________ 
 Relationship to you: _________________________ 
 Email: _____________________________________ 
 Phone: ____________________________________ 
 Address: ___________________________________ 
      ___________________________________ 
      ___________________________________ 
 Name: _____________________________________ 
 Relationship to you: _________________________ 
 Email: _____________________________________ 
 Phone: ____________________________________ 
 Address: ___________________________________ 
      ___________________________________ 
      ___________________________________ 
 
 
Thank you very much for completing this questionnaire. The information you have 
provided has been very helpful and we appreciate your thoughtful answers.  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APPENDIX C: SPOUSE/PARTNER QUESTIONNAIRE 
Please fill out this survey if you are the SPOUSE OR PARTNER of a person with MEN1               ID# 
I have read the description of the study, and I have decided to participate in the 
research project described here.  I understand that I may refuse to answer any (or all) 
of the questions at this or any time.  I understand that my decision about participating 
in this study or answering questions will not affect the care or services that I receive at 
M. D. Anderson Cancer Center.   
During the course of this study, the research team at The University of Texas M. D. 
Anderson Cancer Center will be collecting information about me that they may share 
with health authorities, study monitors who check the accuracy of the information, and 
individuals who put all the study information together in report form.  Information that 
could identify me personally will not be made public.  By answering the questions, I am 
providing authorization for the research team to use and share my information at any 
time.  If I do not want to authorize the use and disclosure of my information, I may 
choose not to answer these questions.  There is no expiration date for the use of this 
information as stated in this authorization. 
Completion of this survey is optional and confidential.  Due to the anonymous nature 
of the study, questionnaires will not be able to be withdrawn once they have been 
submitted.  If you have any questions or would like more information please contact, 
the Clinical Cancer Genetics Program or your genetic counselor at 713-745-7391 or e-
mail ccg@mdanderson.org.  For information on the Notice of Privacy Practices, please 
call 713-792-2933. 
Attitudes Toward MEN1 Genetic Testing in Minors Survey 
Instructions: We are interested in learning about your attitudes toward MEN1 genetic 
testing for healthy children who are under the age of 18. As you may know, the best 
age for healthy children to undergo MEN1 genetic testing is unknown due to several 
medical, social, and psychological reasons.  We wish to learn about your experience 
and attitudes toward such testing.  
Part 1: The following are questions about YOU. 
1.  What is your age: ________ 
 
2. What is your gender?  
 Male    Female 
 
3. Where do you currently live?    State: ______________  Country:_____________ 
 
4. What is your marital status?  
 Single    Married/Long Term Partner    Separated    Divorced    Widowed 
 
5. What is the highest grade or level of schooling you completed? 
 Some high school   
 High school graduate 
 Some college  
 College graduate (4 Year Degree)  
 Associate’s degree 
 Upper-level degree
   72 
 
Please fill out this survey if you are the SPOUSE OR PARTNER of a person with MEN1               ID# 
6. What is your current occupational status? 
 Employed (Full Time) 
 Employed (Part Time) 
 Unemployed (Not seeking a job) 
 Unemployed (Seeking a job) 
 Homemaker 
 Student 
 Retired 
 
7. What is your (combined) annual household income? 
 Less than $25,000  $50,000 - $75,000 
 $25,000 - $50,000  More than $75,000 
 
8.  Please check all of the following that apply to you: 
  I am currently married to someone who has MEN1. 
  I used to be married/partner to someone who has MEN but we are now separated. 
  I have biological children who have MEN1, or who are at risk to inherit MEN1 
  I have step children/adopted children who are at risk to inherit MEN1 
 
9. How many members of your family or your spouse’s/partner’s family have been diagnosed 
with MEN1? 
  None 
  1-2 
  3-4 
  5 or more 
 
10.  Do you or your spouse/partner have any relatives who have died from complications of 
MEN1? 
Yes      No  
If yes, how old were they when they died? __________ 
 
11.  How severely do you feel MEN1 has affected your or your spouse’s family’s health 
and well-being? (Please circle a number on the scale below). 
  
Not at all                                      Somewhat                                                  Greatly 
    1        2   3   4   5 
 
12.  Has anyone in your family been diagnosed with an MEN1-related tumor before 18 years of 
age? 
  Yes       No  If yes, how old were they? _____ 
If yes, how are they related to you (for example, sister, cousin, 
etc.)? _____
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Please fill out this survey if you are the SPOUSE OR PARTNER of a person with MEN1               ID# 
Part 2: The following questions are intended to find out what people know about 
cancer and genetic testing so that we can improve our educational efforts.  This 
is not a test.  We are simply interested in finding out what the general level of 
knowledge is regarding these topics.  Please indicate whether you think each 
statement is true or false, or if you don't know. 
 13 An altered MEN1 susceptibility gene can be 
inherited from either parent. True False Unsure 
14 
If Lisa looks more like her mother than her 
father, she has probably received more of her 
genetic information from her mother. 
True False Unsure 
15 
A person who carries an altered MEN1 
susceptibility gene will definitely develop 
features of MEN1 in his or her lifetime. 
True False Unsure 
16 
Susan is the first born in her family.  Her 
mother, who has MEN1, was also the first 
born.  Thus, Susan has a higher risk of 
developing MEN1 than her younger brothers 
and sisters. 
True False Unsure 
17 
Rick has had genetic testing for an MEN1 
gene alteration that was found in his family.  
His results were negative; therefore, he is not 
at increased risk to develop features of 
MEN1. 
True False Unsure 
18 
Kelly has had genetic testing for an MEN1 
gene alteration that was found in her family.  
Her results were negative; therefore, her 
children are not at risk to inherit MEN1 from 
her. 
True False Unsure 
19 
John’s father has an altered MEN1 gene.  
The chance that John has inherited this gene 
alteration is 50% or 1 in 2. 
True False Unsure 
20 
Once a gene alteration has been detected in 
a person with MEN1, their family members 
can be tested for the gene alteration to know 
for certain whether or not they also have 
MEN1. 
True False Unsure 
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Please fill out this survey if you are the SPOUSE OR PARTNER of a person with MEN1               ID# 
Part 3.  Please think about your experience with MEN1 in your family.  Please 
indicate how frequently each comment was true for you during the past seven 
days. 
  Not at all Rarely Sometimes Often 
21 I thought about it when I didn’t mean to. 1 2 3 4 
22 I avoided letting myself get upset when I 
thought about it or was reminded of it. 1 2 3 4 
23 I tried to remove it from my memory. 1 2 3 4 
24 I had trouble falling asleep or staying 
asleep because of pictures or thoughts 
about it that came into my mind. 
1 2 3 4 
25 I had waves of strong feelings about it. 1 2 3 4 
26 I had dreams about it. 1 2 3 4 
27 I stayed away from reminders of it. 1 2 3 4 
28 I felt as if it hadn’t happened to me or it 
wasn’t real. 1 2 3 4 
29 I tried not to talk about it. 1 2 3 4 
30 Pictures about it popped into my mind. 1 2 3 4 
31 Other things kept making me think about 
it. 1 2 3 4 
32 I was aware that I still had a lot of 
feelings about it, but I didn’t deal with 
them. 
1 2 3 4 
33 I tried not to think about it. 1 2 3 4 
34 Any reminder brought back feelings 
about it. 1 2 3 4 
35 My feelings about it were kind of numb. 1 2 3 4  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Please fill out this survey if you are the SPOUSE OR PARTNER of a person with MEN1               ID# 
Part 4: The following questions ask about your personal feelings about genetic 
testing in healthy minors (in other words, individuals with no medical conditions 
who are younger than age 18).  Please indicate your agreement with each of the 
following statements using the scale below. 
 Strongly 
Disagree 
Disag
ree 
Neither 
Agree nor 
Disagree 
Agr
ee 
Strongly 
Agree 
36 
Children under age 18 
should be given the 
opportunity to be 
genetically tested for the 
MEN1gene alteration  
1 2 3 4 5 
37 
Parents should decide if 
their children are allowed 
to have an MEN1 genetic 
test or not, even if a 
doctor disagrees 
1 2 3 4 5 
38 
Even though some of the 
conditions associated with 
MEN1 may not affect 
people until they reach 
adulthood, children should 
still be offered MEN1 
genetic testing 
1 2 3 4 5 
39 
Children should be 
involved in making the 
decision about whether or 
not they have MEN1 
genetic testing 
1 2 3 4 5 
40 I am in favor of MEN1 genetic testing for children 1 2 3 4 5 
41 
If children are tested and 
they turn out to carry an 
MEN1 gene alteration 
(that is, they test positive), 
they should be told about 
their test result 
immediately 
1 2 3 4 5 
42 
Even if there is no known 
prevention for the 
conditions associated with 
MEN1, children should be 
offered MEN1 genetic 
testing 
1 2 3 4 5 
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43 
If children are tested and 
they turn out to carry a 
MEN1 gene alteration 
(that is, they test positive), 
then this information 
should be shared with the 
child’s pediatrician 
1 2 3 4 5 
44 
I want my child to have 
genetic testing for MEN1 
before age 18 
1 2 3 4 5 
45 
If children are tested and 
they turn out not to carry 
an MEN1 gene alteration 
(that is, they test 
negative), they should be 
told about their test result 
immediately 
1 2 3 4 5 
46 
The benefits of children 
participating in MEN1 
genetic testing outweigh 
the risks 
1 2 3 4 5 
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Please fill out this survey if you are the SPOUSE OR PARTNER of a person with MEN1               ID# 
Part 5: The following list includes reasons some people give for wanting or not wanting to have 
their child have genetic testing.  Please indicate how important you feel each of the following is 
in making a decision to have MEN1 genetic testing for your child using the 1-5 point scale. 
 
Not 
Importan
t 
Slightly 
Importan
t 
Somewh
at 
Important 
Importan
t 
Very 
Importa
nt 
47 
I would be relieved to know my child 
did not have MEN1 1 2 3 4 5 
48 
My own experience with MEN1 
makes me more concerned about my 
child’s risk for the disease 
1 2 3 4 5 
49 I’m afraid I would get too upset 1 2 3 4 5 
50 
I / My child could plan for the future 
1 2 3 4 5 
51 I’m afraid my child would get too upset 1 2 3 4 5 
52 
I am concerned that having the test 
might cause problems with my child’s 
insurance 
1 2 3 4 5 
53 I am concerned about my family’s reactions 1 2 3 4 5 
54 I want to learn whether my child is at risk for MEN1 1 2 3 4 5 
55 I am worried about how it would affect my relationship with my child  1 2 3 4 5 
56 I’m not sure if the genetic test is accurate 1 2 3 4 5 
57 Something could be done to improve my child’s health 1 2 3 4 5 
58 I have a responsibility to let my child know if he/she has MEN1 1 2 3 4 5 
59 I just want to know 1 2 3 4 5 
60 The cost of genetic testing is too expensive for my family to afford 1 2 3 4 5 
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Please fill out this survey if you are the SPOUSE OR PARTNER of a person with MEN1               ID# 
61.  What do you feel is the ideal age for an individual to have MEN1 genetic testing? 
Why did you choose this age?  
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Please fill out this survey if you are the SPOUSE OR PARTNER of a person with MEN1               ID# 
The following questions are optional: 
Please indicate if we may contact you by phone with any follow up questions:  
 Yes  No 
 Name: __________________________________ 
 Phone Number: __________________________ 
 
We would like to include as many people as possible in this survey.  Individuals with 
MEN1 and their spouses/partners are eligible.  Please tell us about any friends or 
relatives who may be interested in participating in our study: 
 Name: _____________________________________ 
 Relationship to you: _________________________ 
 Email: _____________________________________ 
 Phone: ____________________________________ 
 Address: ___________________________________ 
      ___________________________________ 
      ___________________________________ 
 
 Name: _____________________________________ 
 Relationship to you: _________________________ 
 Email: _____________________________________ 
 Phone: ____________________________________ 
 Address: ___________________________________ 
      ___________________________________ 
      ___________________________________ 
 
 
Thank you very much for completing this questionnaire. The information you have 
provided has been very helpful and we appreciate your thoughtful answers. 
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APPENDIX D: REMINDER LETTER 
Clinical Cancer Genetics Program 
T 713-563-1908  F 713-745-1921 
Unit 444 
1400 Hermann Pressler Dr 
Houston, TX 77030-4008 
 
Date 
Name 
Address 
Dear Ms./Mr. <Name>: 
Over the last several weeks we have tried to contact you at the above address about our study 
Parental Attitudes of Predictive MEN1 Genetic Testing in Minors.  As of <the date shown at 
the top of this letter>, we have not received the questionnaire back from you nor have we 
received a refusal to take part in this study.  It is possible that you may have sent in your 
survey and our records have not been updated yet.  If you have already completed the survey, 
thank you for your response and please disregard this letter. 
We are interested in obtaining information about parental attitudes toward MEN1 predictive 
genetic testing in their healthy children.  The questions that you will be answering will help the 
researchers and physicians to better understand the needs of families with children at risk for 
MEN1 and provide the appropriate services. Participation in the study involves completing a 
questionnaire. 
If you are interested in taking part in this study and have lost the questionnaire, we have 
enclosed another copy for your convenience. Patients who have been diagnosed with MEN1, 
please complete the white survey.  Spouses or partners of persons with MEN1 please 
complete the yellow survey.  We are interested in responses from both patients and spouses 
but responses will still be included even if only one person is available to participate.  If you do 
not wish to take part in this study, please indicate this and also return the blank questionnaire 
to us in the pre-addressed envelope.   
If you prefer the online survey, please go to http://www.surveymonkey.com/s/MEN1inminors 
and follow the instructions.  You will need to enter your ID user number, which is <insert ID#>.  
The online survey consists of the same questions as the one that is included in this packet and 
was created using a professional account on Survey Monkey, which is a confidential survey 
making tool.  Your response will be maintained strictly confidential and will only be shared with 
study staff.   
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Completion of this survey is optional and confidential.  Due to the anonymous nature of the 
study, questionnaires will not be able to be withdrawn once they have been submitted.  If you 
have any questions or would like more information please contact, the Clinical Cancer 
Genetics Program or your genetic counselor at (713) 745-7391 or e-mail 
ccg@mdanderson.org. Thank you very much for considering this invitation to participate in our 
study. 
 
Sincerely, 
 
Katie Rock, BA  Thereasa Rich, MS, CGC  Elizabeth Grubbs, MD 
Genetic Counseling Intern Genetic Counselor   Assistant Professor 
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APPENDIX E: OPEN ENDED SUREVEY RESPONSES 
• I would say when they are reaching puberty or early teens. I feel that if it is done early 
on, i.e. infancy, then it would cause unnecessary heartache when it is important to be 
bonding with your child. I also think there is less risk at infancy and younger years of 
having complications due to MEN1. I feel at puberty the child is old enough to involve 
themselves in whether they want the testing and their maturity level would help them 
understand to some extent a very complicated diagnosis. 
• Being a female, I began showing signs around the age of 13 or having female problems, 
also they may start to get the mole like spots on the face. 
• 8-10 
• 1. It could happen at any age. Very concern  2. There is no age of when humans get 
MEN1 it just develop in your system. By that time it mite be to late for processes 
• It's a independent decision for each parent. I found out that I had MEN1, back in 1995 
when I was 33. My daughter, at the time was 14. I stressed and worried over the fact 
that I could of passed the gene onto her. Not knowing was stressful. Finally, in 2003 we 
found out that genetic testing was available (here at MDAnderson) my daughter was 22 
- We definitely wanted the testing. She was getting married and considering starting a 
family, she also wanted to know. Luckily, she was negative to carry for gene. If genetic 
testing was available to us back in 1995, we would choose to have her tested. 
• Not sure, depends on maturity of child, but probably 12 or 13 years old. Old enough to 
understand ramifications/consequences. 
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• By age 10. So you can start monitoring the markers (calcium, Prolactin, PTH, gastrin, 
etc.) if tested positive. 
• I feel a child should be tested as soon as doctor's are confident that results would be 
accurate. If there is any chance of change of testing I would have peace of mind in 
having a second testing done. I do not feel it is ever too early to be on the lookout for 
symptoms with MEN1. As negative result is best, at least with a positive result we can 
be more cautious with our children as they mature. Personally I have doubts as to where 
I would be now had I not have known about my condition only because of my family 
history. 
• I was diagnosed at 34 after pancreatic cancer surgery. My father was diagnosed two 
years after me! My twins were very mature at age 14 and we talked about testing and 
what it might mean. They both wanted to be tested. They wanted to know the results 
whether good or bad. (obviously you would tell them if negative to celebrate and avoid 
anxiety.)  
I was devastated to find out my boys were positive. They are identical so we knew the 
chance that if one was positive, both likely would be. 
Since diagnosis, my boys have yearly screening and when one son had a blood sugar 
issue, we acted quickly to rule out a PNET. 
• 16-18,  Most young people, at this age, would have some level of maturity to 
understand what genetic testing is and why it might be important for them personally. 
They may have seen a grandparent, parent or sibling deal with the presentation of 
symptoms or surgery and testing could enhance their knowledge. By this age some 
could have had opportunity to study biology and all the new ways technology is 
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discovering more specific and accurate health data. Most would have completed puberty 
and have some stabilization of hormones. 
• At any age that the child could understand what illness is. That things can go wrong 
with your body. That its not your fault. 
• As a parent, I would like to know if son was + or - before puberty onset. 
While I realize that some individuals handle information differently, I would like to 
start a baseline for certain tests and choose an acceptable monitoring schedule through 
pediatrician or other dr. For kids, I do not think it would need to be as frequent as adults 
with manifestations. My MEN has been monitored/addressed proactively and as a result 
does not impact my life in a major or negative way. I hope the same for my son. 
Information allows one to plan…and if necessary anticipate. I prefer to have as much 
info as possible. I do not feel that a child (younger than 18) needs to know…unless the 
disease manifests itself in some way…and even then some concepts may be beyond 
their grasp. My opinion may shift if test results impacted insurance options now or in 
future. 
• About age 25 when they are somewhat more mature and can make better decisions 
about their lives. 
• 17. They should be old enough to handle the results and are still living at home. 
• I wouldn't support the testing for children under 12, but 12-18 is appropriate. 
It's an individual choice. If family members exhibit symptoms, the testing may be more 
important. 
• 13, they will be more understanding 
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• I don't feel the age of the test is as important as when the child is told/explained about 
the disease 
• As soon as possible --> had my M EN1 been discovered earlier, it likely would have 
resulted in less-invasive surgery. The tumors could have been removed earlier and 
saved me a more healthy pancreas. 
• 14 - old enough to understand the situation. 
• 18  Knowledge is power. Knowledge can overcome fear. 
• 14 years of age. They may be able to better understand the ramifications of MEN1 
related medical problems. 
• In my family, MEN1 has not been an issue until late teenage years (symptom wise). I 
feel during the child's teens would be a good time to test and explain to the child what it 
is. I don’t see a sense in putting the stress into a child’s life if there is no preventative 
care needed. Once the child knows MEN1 could be a factor in their health they should 
be tested. I felt more stress waiting for the test results than I have felt since knowing I 
have MEN1. In the end I would like my child to make that decision for herself and 
share my experience with her to help her decide. 
• Not qualified to say. I feel it is important to know as soon as possible and educate all 
involved including medical professionals. 
• 17 yrs old  This is an age that a child can become more responsible and able to 
understand the diagnosis. The decision can be made in regards to family planning. This 
is also the age most of my family began to have symptoms of high calcium and kidney 
stones. Therefore, the diagnosis would have been made prior to symptoms and not be an 
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"elephant in the room." It is better to know than to have an unknown hanging over your 
head. 
• 17 young enough to understand, but old enough to be able to handle the condition. 
• Before the age of 10. My experience was that my hyper-parathyroidism was already 
present at age 11. It's also my opinion that if a child is diagnosed younger that they will 
accept MEN 1 and the resulting exams/testing as a 'normal' part of their life. 
• I believe that the ideal age for someone to have genetic testing for MEN1 should be 
around 6-8 years old. I say that because that is about the time I started being a "sickly" 
child and went for years with no answers as to what was going on. I also believe that if 
they would have tested me for MEN syndrome when they found my first pituitary tumor 
and was on synthoid at the time. Basically, where I come from they have never heard of 
such and just kept giving me meds that didn't work and the problems were getting 
worse. I have to travel hours to Dallas or Houston to find someone to treat me because 
all of the local doctors just look at me and say that I have way too many problems and 
am way to complicated. 
• Before 10 - Not Sure Really 
• 13..so that as a young adult children can have the pros and cons carefully explained to 
them 
• I am not sure there is a good age. Mine was detected by accident I will never know if all 
of the pain, anguish and worry has been for nothing. maybe I would have got though to 
old age with no problems. Instead I now live in fear. I have had 2 operations in the last 
3 years but never had a single symptom. I rarely saw a doctor and thought I was fitter 
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than all of my peers leading a physically active lifestyle, never had a day off sick. I 
considered I was a particularly optimistic and strong person, I am now in receipt of 
councelling. It is known that stress affects the immune system- so is causing stress 
going to make the development of tumours more likely? This is a Kafkaresque world. I 
wouldn't want to put this onto any one else and certainly not a young person. Should an 
easy "cure" be forthcoming of course this changes everything. 
• Would rather treat symptoms then worry about having the genetic mutation. If a family 
member is in a research trial that does the testing, then so be it. But once there is a 
positive in the family, I don't feel any other family member needs to be genetically 
tested. Again it is about treating the symptoms not the genetic test. 
• 25. Ideal age to make informed decisions 
• Age 10 because they are old enough to understand but young enough to process the 
information for a long time before signs/symptoms. Also, in the rare case the child may 
already need treatment at a young age. 
• I am not sure what the ideal age would be. 
• 21/22 Except in exceptional circumstances, once adult education is completed 
• 5-10 years old. Tumors have been shown to develop this early, so in addition to 
psychological benefits of a negative test, one saves money on annual screenings. If 
positive, the risks for insurance, etc. seem outweighed. Also, they are old enough to 
learn about MEN. 
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• At birth. Less traumatic for the child (who wont remember having it), and gives parents 
options with regard to age to begin screening etc. I have heard that children as young as 
5 have shown symptoms 
• 10. It seems like a reasonable age for a child to begin to understand the implications of a 
genetic test and a genetic disorder. 
• I think a child should be tested whenever their parents think, My son will be tested in 
the new year when he reaches 5, and my youngest may get tested before that age. My 
eldest is being tested when he turns 5 because it is the recommended age here in the 
UK, all of my family history has shown that we suffer with MEN 1 symptoms from an 
early age and I think my child has the right to know what may or may not happen in his 
life, if the test is positive he will be told when he can understand what it means and he 
can make the decisions about the screening. My mother died at the very very early age 
of 34 when her children were just 11 and 13, this impacts my decisions also because my 
sons both need to understand why their grandma isn't here and also why their mummy is 
sometimes in hospital. They deserve to know whether they have MEN regardless of 
age. 
• I didnt have a choice at a younger age. the family was unaware of the condition. until 
my late 30s at which point I had suffered for years. I was tested positive at 40 
• 10 years old 
• 16 as i would want them to have the ability to make an informed decision and to be able 
to manage the concequences mentally and physically if necessary 
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• Ten years old is the age offered to children in Scotland. I feel this is young enough 
unless they show signs of the illness before this age, as they don't really understand 
what is going on. Emotionally it is very difficult for them too. My child had a positive 
diagnosis at the age of ten and has been quite unwell over the last two years from age 12 
to 14. so for me, the genetic testing was important and it now means that my daughter is 
kept under medical supervision which puts our minds at ease. Admittedly though she 
has found the diagnosis difficult mainly because she has watched myself (her mum), 
struggle with the illness since she was little and doesn't want to go through what I am 
going though. It scares her about what the future may hold for her. 
• As soon as MEN is known for a parent. It can help in how to approach healthcare. If 
there are tumors it is better to find them early. 
• 16- 
• I would say 15-18 is a good age, as before that you won't necessarily understand the 
condition and it's implications and you also have the emotional maturity to deal with it 
(though 15 - 18 can be a testing time anyway!) In addition I would also suggest that 
testing before 2 years of age is appropriate too as it means that having the condition is 
normal, so no emotional adjustment is needed (if that makes sense). 
• From birth if there is already MEN1 in the family or ASAP if they show any signs 
• 10. This is when I developed symptoms 
• If insurance isn't a problem then as early as possible, there are cases of 
hyperparathyroidism developing in pre-school children, therefore I feel its important to 
start checking early as possible to avoid long term health problems. 
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• The age would depend on the individual's health and ability to understand the issues. If 
a child of a parent with MEN1 is unwell with symptoms that could be due to an MEN1 
related tumour then this is an argument in favour of doing the test at that point, but if 
the child remains healthy, I would think it preferable to wait until the child is able to 
participate in such a decision. As children mature intellectually and emotionally 
differently, and their family circumstances differ, I think this should be decided on an 
individual basis with no prescribed age. In countries other than the UK, the issue of 
insurance difficulties would be a strong factor against testing both of minors and adults 
(health insurance is universal, free and very comprehensive in the UK - and the test 
itself is paid for by the national health service, so this is not a concern in the UK). 
• 10, when the child can understand some of it, but before getting to be a teenager when it 
became more traumatic 
• I would like to know as soon as a child is born. If the test is positive you can keep a 
close eye for any MEN1 symptoms as early as needed to keep the childs health as good 
as possible. 
• 5 YEARS OLD, BECAUSE YOU CAN EXPLAIN TO THEM WHY THEY ARE 
HAVING THE TEST & FOR FUTURE MONITORING. 
• Age 8, earlier the better. Enabling doctors with the information to treat her for all 
medical issues is critical 
• 4. At age 4 the child's parents could make decisions about possible procedures before 
their child begins school. 
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• 10-12 From a developmental viewpoint since it affects the pituitary which can effect 
hormone levels etc which may or may not have developmental impact during teenage 
years 
25+ From insurance perspective - can be difficult to get insurance on own unless part of 
a group coverage. Maybe that has changed with new insurance laws 
• With a child that started having trouble at 13 and always feeling that we were "behind 
the curve" on dealing with medical issues, I feel anywhere from 8-12 years of age is 
appropriate? 
• 8-10years old, They can understand it more. 
• If symptoms appear (kidney stones, thyroid, parathyroid, pituitary abnormalities) then I 
would encourage earlier gene testing. If symptom free (according to blood work) I 
would delay testing until after 18 or 21. Great concern is for health insurance and job 
hiring prejudice of having "preexisting condition." 
Also of great concern is the psychological effect at any age of having this diagnosis 
hanging like a black cloud, if some family member (like my daughter) had severe 
consequences- even if they came on after 40. 
Important to note: 
We did not learn of my husband's MEN1 until we were in our 60's. It would have made 
a difference in our family planning if we had learned of this in our 20s. 
Thank you. Glad to help in any way we can. 
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